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CHAPTER 1: 
GENERAL INTRODUCTION 
  
General introduction  Lysyl oxidase 
  |4 
1.1. Lysyl oxidase 
Lysyl oxidase (LOX) is a copper-dependent class of amine oxidases, overexpressed in 
hypoxic tumour and implicated in the metastatic formation process.  The rule of a hypoxic 
environment in tumours and the possibility of study LOX as a pharmaceutical target, to 
develop new anti-cancer drugs, were discussed below. 
1.1.1.   Hypoxia in tumours 
Hypoxia is an event characterized by a lack of oxygen. The concentration of O2 can pass 
from 35 mmHg, in case of hypoxia-induced resistance to immunotherapy, to 0,02 mmHg, 
in the case of the changing on the oxidative state of cytochromes, but a standard level to 
identify an hypoxic environment has not been established yet. Although many solid 
tumours present hypoxic areas with low levels of O2 partial pressure, respect of the normal 
tissues, but these levels can change a lot, because of the unstable oxygenation in tumours 
(Figure 1).  
 
Figure 1. Oxygenation levels in tumours and in normal tissues. (ND: No data available) [1] 
This hostile environment, due to an abnormal vasculature and a reduced blood perfusion, 
is one of the causes of the metastatic process and aggressive form of tumours. In fact, the 
runaway cell growth leads to the formation of extended masses, which can obstruct the 
blood vessels, provoking a reduction of the flux and O2 levels (Figure 2). Therefore, hypoxia 
is characterized by two situations:  
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- Acute hypoxia, where functional and structural alteration of the microvessels 
conducts to a limited perfusion, caused by the obstruction of the masses; 
- Chronic hypoxia, where the altered diffusion geometry reduces the O2 
concentration in the cells, distant about 100 µm from the vessel, causing a stable 
level of hypoxia [2].  
 
 
Figure 2. Blood vessels in normal tissues (a) and in tumours (b). 
 
All these mechanisms are regulated by hypoxia-inducible-factors (HIFs), which promote the 
transcription of many proteins, fundamental for hypoxic cell’s survival. The angiogenesis 
process is a response to the lack of oxygen, and is favorited by HIFs with the enhanced 
expression of two modulator factors: angiopoietin-2 and VEGF-A (vascular epithelial 
growth factor-A). Angiopoietin-2 inhibits the vasculature-stabilizing factor angiopoietin-1, 
provoking the consecutive destabilization of the mature capillaries. Then is able to active 
VEGF-A, which induces the growing of neonatal capillaries in hypoxic areas of the tumour.  
Another function controlled by HIFs is the cell-cell adhesion, destructed by the reduced 
level of E-cadherin, to facilitate the tumour invasion. This process is due to the 
overexpression of LOX mRNA (caused by HIF-1α), responsible of the degradation of Snail 
protein that impedes the expression of E-cadherin [3].  Hypoxia is a predictor of the 
formation of aggressive solid tumours, and of the resistance to single and multicomponent 
chemotherapy. This reduced efficacy is due to the abnormal vasculature and irregular 
blood flowing, impeding the access of hypoxic areas to the drugs. In addition, radiotherapy 
is useless in hypoxic tumours, in fact, compared to the normoxic cancer cells, three times 
higher doses of radiation are necessary to produce the same therapeutic effect.  
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1.1.2. The LOX Family 
Lysyl oxidase is a copper-containing enzyme, where the CuII ion is situated in the catalytic 
site, bound to three Histidine residues. In this site, the organic cofactor LTQ (lysine 
tyrosylquinone) attaches the primary amino group of the substrate, starting the catalytic 
cycle. It is necessary to oxidase the ε-amino group, of the peptidyl lysine, to peptidyl 
aldehyde (α-aminoadipic-δ-semialdehyde, AAS), by consuming O2 and water, and 
producing NH3 and H2O2 (Figure 3). The copper ion is probably required to the re-oxidation 
of the cofactor. 
 
 
Figure 3. Catalytic cycle of LOX. 
 
 LOX family is comprised of five paralogues, LOX and LOX-like 1-4 (LOXL1-4), characterized 
by a highly conserved carboxyl terminus, in which are contained the copper-binding motif, 
the LTQ cofactor and a CRL domain (cytokine receptor-like). The proteins are very divergent 
in the N-terminal part, considering that LOXL2, LOXL3 and LOXL4 contain four scavenger 
receptor cysteine-rich (SRCR) domains, probably involved in cell adhesion. Whereas LOX 
and LOXL1 contain pro-sequences, necessary to the interaction with the extracellular 
matrix (ECM). These pro-sequences were released from the catalytically active enzyme, 
through the processing made by BMP1 and BMP1-related proteinases (Figure 4).  
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Figure 4. Structure of the five LOX prologues [4]. 
The primary function of LOX family is the formation of covalent crosslinks in collagen and 
elastin, which are part of the extracellular matrix (ECM), fundamental for the structures of 
many tissues. In fact, the aldehyde group of AAS bounds covalently the NH2 group, of an 
unmodified peptidyl lysine, to obtain dehydrolysinonorleucine (deLNL), or an aldol 
condensation product (ACP), if it attaches another AAS (Figure 5). These structures 
constitute the covalent cross-linkages of collagen and elastin [5]. 
 
 
Figure 5. Covalent cross-linkages catalysed by LOX. 
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LOX mRNA is expressed especially in aorta, lung, kidney and pancreas, but its expression 
decreases during ageing, with the reduced formation of tropoelastin and collagen. LOXL1 
was found in aorta, placenta, skeletal muscle, kidney and pancreas, whereas LOXL2 is 
abundant in prostate, uterus and placenta. LOXL3 and LOXL4 are less expressed than the 
previous proteins, but the presence of LOXL3 was found in placenta, uterus and heart, while 
LOXL4 in placenta, lung, kidney, pancreas, testis and ovary. All the five LOX proteins 
influence the cell adhesion, the motility and cells proliferation, regulating the transcription 
and translation process, inside and outside of the cell. These several functions, joined to an 
upregulation and downregulation, indicate a role of LOX family as both tumour suppressors 
and promoters. In fact anomalous activities, in the extracellular matrix, have been reported 
for LOX and LOXL2 [4], suggesting a role in the tumour invasion process. In particular LOX 
was connected to various cancer types, such as head and neck squamous cell carcinoma 
(HNSCC), and breast, colorectal and prostate cancer, ductal carcinoma in situ, due to its 
increased expression. However, the initial studies had pointed to a suppressor activity of 
LOX, thanks to an inhibitory effect on oncogenic HRSA-mediated transformation, and other 
similar situations. Progressively, this suppression effect has attributed to the LOX pro-
peptide. Enhanced levels of LOXL2 were associated with the desmoplastic region, often 
found in aggressive tumours. A suppressive role for LOXL2 has also been considered in a 
few studies, although some have furnished conflicting results, unable to validate this 
theory.  Other reported data, referred to LOXL1, LOXL3 and LOXL4, evidenced the different 
functions of this protein family, depending on the multiple temporal and spatial expression 
patterns, and the ambiguous roles in tumorigenesis [4]. Nevertheless, LOX and LOXL2 are 
widely correlated with reduced number of tumours regressions, with the decrease of 
survival, in many cancer studies. In detail, LOX overexpression can be associated with 
hypoxia in human breast (MDA-MB-231 cancer cell line), cervix (SiHa cancer cells) and 
head-neck tumours [6]. Instead, LOX was not found in the non-metastatic human breast 
cancer phenotype MCF-7; this consideration intensifies the connection between LOX and 
metastasis, demonstrating that the enzyme is not involved in primary tumours. The 
treatment of LOX with the extracellular copper chelator BCS (bathocuprione disulphonate) 
furnished a reduced invasion, therefore, only the catalytically active enzymes, secreted in 
the ECM, are involved in the metastatic process. Furthermore, the synthesis of LOX is 
stimulated by HIF-1 [6], so these proteins can act in the metastatic invasion. This can be 
explained by the remodelling of the microenvironment, due to the elevated expression of 
ECM components. In fact, LOX proteins alter the ECM structure, causing the formation of 
local stiffening, which leads to malignant tissues. The angiogenesis hypoxia-inducted, 
joined with the process of epithelial-to-mesenchymal transition (EMT), leads to an 
increased invasion and migration, which are the origin of the metastasis. The invasion 
process in the bloodstream is due to the remodelled ECM, which favourites the migration 
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of the tumour cells to a secondary site (Figure 6). In the case of breast cancer cells, the 
formation of a “premetastatic niches” is a further information for the metastatic disease 
[7]. The enhanced LOX-mediated level of collagen modifies the basement membrane, 
inducing the invasion of CD11b+ myeloid cells in this premetastatic site. These cells adhere 
to collagen, producing matrix metalloproteinase-2, which promotes the formation of 
clusters of BMDCs (bone marrow-derived cells), consisting in the premetastatic niche. 
Moreover, in the breast cancer cell, the process of migration and adhesion seems to be 
regulated by a hydrogen peroxide-mediated mechanism. In fact, the removal of H2O2 by 
catalase treatment led to a dose-dependent loss in the activation of Src kinase, a 
fundamental protein in the adhesion process [8]. 
 
 
Figure 6. Tumour progression and metastatic process. 
 
 
1.1.3. Therapeutic targeting strategies 
LOX family is an extracellular class of enzymes, with a low expression in the normal tissues 
respect of the hypoxic tissues. Despite the apparent opposing roles as both tumour 
suppressors and promoters, these proteins can be studied as drug targets against cancer. 
One of the possible approach is the inhibition of the enzymatic activity of LOX, using small 
molecules, such as BAPN, or antibodies. In this second option the use of a nonspecific LOXL2 
monoclonal antibody, D-penicillamine (DPEN), is an example of inhibition. However, DPEN 
had initially been used in rheumatoid arthritis, biliary cirrhosis, Wilson’s disease and 
cystinuria, demonstrating a lot of side effect. Another enzymatic inhibition resource is the 
use of bispecific antibodies, targeting multiple LOX family proteins, but this way is still to 
investigate.  The second approach consists of targeting the processing and activation of 
LOX, such in the case of pro-LOX and pro-LOXL1, mediated by BMP1. However, this 
proteinase is important also in bone and cartilage development, reason why its use as a 
target is impeded. The third strategy to block LOX family is the alteration of cellular 
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response to the ECM remodelling. Integrins, which contribute to this process, can be 
considered as possible target, but the previously developed integrin inhibitors have not 
showed positive results yet. The last attempt involves the transcriptional or translational 
effects, for example by inhibiting HIF-1α. Some studies showed this inhibition leads to a 
reduced expression of LOX in vitro, reduced tumour progression and metastatic process, in 
mouse models of breast and colorectal cancer [9, 10]. A combination of the described 
therapeutic approaches (Figure 7) is a potential way against solid hypoxic tumours and 
metastasis.  
 
 
Figure 7. Possible therapeutic targets. 
 
The crystal structures of LOX family has not been completely understood yet, reason why 
screening methodologies and classical drugs development are impossible. In fact, the only 
developed small inhibitor molecules are non-selective for the hypoxic regions.  One of the 
most important LOX inhibitors is BAPN (β-aminoproprionitrile), which is used as a reference 
in the experimental studies (IC50= 10 µM). BAPN irreversibly inhibits LOX, probably 
attaching the LTQ cofactor with the NH2 group, to form a covalent bond in the catalytic site. 
Its unselective action causes unwanted biological interactions, and consecutive side effects, 
due to its small molecular structure. BAPN acts also in the phenomenon of lathyrism, since 
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it is widely contained in sweet peas (Lathyrus odoratus) [11]. This pathological situation is 
observed in children and animals, in case of indigestion of these legumes.  
 
 
 
Figure 8. Structure of BAPN. 
Excluding BAPN, other LOX inhibitors are presented in literature and are classified in 
primary amine-derivatives (as BAPN), hydrazine-derivatives and heterocycle-derivatives. 
All these molecules are characterized by a basic group, pointing at a favorited cationic 
substrate for the interaction with LOX. All the three classes of inhibitors furnished many 
side effects, due to the non-specificity, but also to the presence of reactive or toxic 
functional groups. For this reason, the development of LOX inhibitors, as anticancer drugs, 
is not possible. Only the pyridazinone-derivatives (Figure 9, circled in red), characterized by 
a different structure, have exhibited a high activity against scleroderma and fibrosis, but 
also in these situations the lathyrism effect may occur, due to  a systemic LOX inhibition, 
which produces the reduction of collagen in many organs. 
 
 
 
 
Figure 9. Structures of other LOX inhibitors. 
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1.1.4. Hypoxia activated prodrugs (HAP) 
 
Considering that BAPN and other LOX inhibitors cannot be developed as common drugs, 
because of their undesirable side effects, a strategy as antimetastasis therapy are the 
hypoxia-activated prodrugs (HAP). These molecules are stable analogues, able to deliver 
selectively the effective drugs, under hypoxic conditions. The chemical structures of HAP 
are classified in four categories: nitro aromatic compounds, aromatic N-oxides, aliphatic N-
oxides and Quinones, where the nitro aromatics are the most efficient masking groups.  
 
 
Figure 10. Examples of HAPs. 
The activating mechanism of the nitroaromatics is characterized by an “electronic switch”, 
due to the reduction of an electron-withdrawing NO2 group to an electron-donating 
hydroxylamine, causing an increase of the electron density of the aromatic moiety [12]. In 
fact, a chemically reducing environment marks out the hypoxic tumours, where various 
reductases (as POR, MTRR, NDOR, iNOS) exhibit their action. In the cellular system NADPH: 
cytochrome P450 oxidoreductase (POR) is the most active enzyme, among the other 
diflavin reductases, and maybe the most involved in HAPs reduction. In general, the process 
starts with a one-electron reduction on the nitro-HAP, producing a radical anion. This anion, 
in a disproportionation reaction, is converted to a nitroso compound, successively reduced 
N-oxides 
Quinones 
Nitro 
aromatics 
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to hydroxylamine, and then, eventually, to amine. This situation is common in the hypoxic 
cells, whereas in the normoxic cells a “futile redox cycle” impedes the HAP activation. In 
fact, the reduced radical anion is immediately oxidized back, by O2, to the initial nitro-HAP, 
where the oxygen molecules are reduced to free radical superoxide (Figure 11). This radical 
can induce several damages in cells, but it is inactivated by superoxide dismutase, furnished 
by the natural antioxidant defences.  
 
Figure 11. Activation process of nitro-HAPs. 
 
The nitroaromatic masking groups were widely used to release several LOX inhibitors and 
other anticancer agents, taking advantage of the reducing hypoxic microenvironment. In 
general, the electronic switch leads to changes in the physiological and physiochemical 
activity, inducing the release of the active drug in two mechanism. The first possibility is 
the direct modification of the HAP structure, the second is the molecular fragmentation of 
the prodrug in several parts, containing the concrete anticancer molecule. This second 
mechanism is more attractive, because many alterations in the structure may deface the 
pharmacokinetic and cytotoxicity properties. In fact, in the case of nitro-benzyl or other 
nitro-aryl (with a methyl as linker) derivatives, the fragmentation process consists of a 
spontaneous 1,6-elimination, to release the active molecule, after the reduction of NO2 
group to hydroxylamine (Figure 12).  
 
 
Figure 12. Fragmentation process in nitroaromatic-HAPs, by 1,6-elimination.  
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Another important consideration in the action of HAP is the “bystander effect”. This 
phenomenon consists of the killing of nearby cells by the active drug, released from 
prodrug-activating cells [3]. Bystander effect can expand the HAP’s antitumor effects to the 
moderately hypoxic tumour cells, beyond just severely hypoxic cells, but, to carry out this 
possibility, the active released drug must be stable. In fact, the molecule passes through 
the surrounding tissues by diffusion, reason why stable drugs arrive at the normoxic cells 
more easily than highly reactive drugs.  
 
Some example of nitro-aromatic HAPs, currently used in clinical trials, are PR-104, TH-302 
(Figure 10), and KS119. These prodrugs are progressively discussed. The first one is a water-
soluble phosphate ester of a dinitrobenzammide mustard, connected to a bromide and a 
mesylate substituents. An initial hydrolysis of the phosphoric ester leads to the PR-104A 
form, which is then activated by a direct-modifying mechanism. The reductase, contained 
in hypoxic cells, convert PR-104A to PR-104H (Figure 13), the hydroxylamine form, 
subjected to nucleophilic substitutions. The generated halogenated metabolites result to 
be the most important contributors for the bystander effect, and more potent of PR-104H. 
The effective action as anticancer agent is the cytotoxicity on the DNA cross-linkags. At 
present, PR-104 is tested in four phase 2 clinical trials [3]. 
 
 
 
Figure 13. Structure of hydrolysed PR-104. 
 
Another important HAP example is TH-302, named also Evofosfamide. This is a 
nitroimidazole-triggered phosphoramidate mustard, in which the phosphoryl group is 
connected with two bromoehtyl-monosubstituted nitrogen atoms. The fragmentation 
process, liberating a phosphoramide portion (Br-IPM) and a benzyl-type radical, which 
evolves to the trigger-H compound (Figure 14), activates the prodrug. Br-IPM is the active 
drug, which is involved in a cytotoxicity on the DNA cross-links, with the support of the 
bystander effect. The monosubstitution on the nitrogen atoms promotes the stability, as 
further alkylated compounds are susceptible to the oxidation, made by cytochrome P450. 
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Evofosfamide is currently applied in two phase 3 clinical trials, in combination with 
gemcitabine for the treatment of pancreatic adenocarcinoma, and with doxorubicin [3].  
 
 
Figure 14. Activating process of TH-302. 
 
The last reported example is KS119, a nitrobenzylcarbonyl of a hydrazine alkylating. The 
initial reduction converts the prodrug into hydroxylamine derivative, which subsequently 
decomposes to three parts: hydroxyl imine, CO2 and the hydrazine 90CE (Figure 15). This 
last molecule undergoes an elimination, forming reactive ethylating species that cause 
guanosine-cytosine cross-links. 90CE is the active drug, characterized by a short half-life 
(t1/2 = approx. 30 seconds), but it exhibits a strong bystander effect.   
 
 
 
Figure 15. Activating process of KS119. 
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1.2.  Monoacylglycerol Lipase 
Monoacylglycerol lipase (MAGL) is an intracellular serine hydrolase, implicated in many 
physiological processes, such as lipolysis and the metabolism of 2-arachidonoylglycerol (2-
AG), which is one of the most important endocannabinoids. The role played by this enzyme 
in inflammation, neuroprotection and in cancer diseases was discussed below. 
 
1.2.1 The Endocannabinoid system 
In 1990 a G-protein coupled receptor (GPCR) binding cannabinoids was cloned and named 
CB1 cannabinoid receptor; subsequently the second peripheral cannabinoid receptor, CB2, 
was cloned too. These proteins are the target of Δ9-tetrahydrocannabinol (Δ9–THC), the 
main psychoactive constituent of Cannabis Sativa, but small lipid mediators, known as 
endocannabinoids (eCBs), also activate CB receptors. The principle molecules of this class 
are N-arachidonoylethanolamine (also named anandamide or AEA) and 2-
arachidonoylglycerol (2-AG). CB1 and CB2 receptors belong to the superfamily of receptors 
that couple to guanine-nucleotide binding-proteins (G-protein) and possess seven 
hydrophobic transmembrane segments connected by alternating extracellular and 
intracellular loops. The C-terminal domain is intracellular and joined to the G-protein 
complex, instead, the N-terminal is extracellular and glycosylated. The receptor share 48% 
amino acid sequence and they diverge in signalling mechanism, tissue distribution, and the 
response due to several ligands [13]. The endocannabinoid system is characterized by a high 
variety of signal transduction and a diffused distribution of the receptors, both at central 
level and in the periphery. The CB1 receptors, in the central nervous system, control 
memory, learning, pain, appetite, movement, psychoaffective state and neuroprotection, 
whereas in the periphery the CB2 receptors is involved in inflammation and immune 
response. CB1 receptors are expressed also in the periphery, even if in lower levels, as in 
immune and reproductive system, liver, intestine, vascular endothelium, and peripheral 
nerve synapses.  
 
 
Figure 16. Structure of CB1 and CB2 receptors. 
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The mechanism of the endocannabinoid system is a retrograde signalling [14]. This way is 
used to convey information, about the activity of neurons, back to cells that were 
innervated, producing a transient or prolonged reduction in the release of 
neurotransmitters. In fact, postsynaptic receptors, like AMPA and NMDA, are activated by 
the neurotransmitters, causing the influx of Ca2+ and the biosynthesis of anandamide and 
2-AG. Postsynaptic neurons secreted the synthesized endocannabinoids in the synaptic 
cleft, to active CB receptors, in the presynaptic terminal. Then CB receptors couple through 
the Gi/Go-proteins, to regulate ion channels and inhibit neurotransmitter release. The 
activation of CB1 or CB2 receptors typically blocks adenylate cyclase, preceding through 
cyclic AMP, and regulating cAMP-dependent kinase A (PKA) protein functions. In the case 
of AEA, the biosynthesis in the nervous system is incompletely clear, but the canonical 
pathway conveys a transacylation- phosphodiesterasation. In fact, the arachidonic acid of 
membrane phospholipids reacts with the amine of phosphatidylethanolamine (PE), by a 
calcium-dependent transacylase enzyme, to form N-arachidonoyl 
phosphatidylethanolamine (NArPE), hydrolysed to give anandamide (Figure 17). This step 
is catalysed by a NAPE-selective phospholipase D (NAPE-PLD), which is a phosphodiesterase 
of the metallo-betalactamase family [15]. Therefore, also two pathways, distinct from NAPE-
PLD have been identified. 
 
Figure 17. Biosynthesis of anandamide by NAPE-PLD pathway.  
  
The 2-AG biosynthesis is characterized by the formation of 1-acyl-2-arachidonoylglycerol 
(DAG), from the precursor phosphatidylinositol-4,5-bisbphosphate, thanks to 
phospholipase C activity (PLC), followed by the hydrolysis of DAG, by diacylglycerol lipase 
(DGL). An alternative pathway to PLC-driven DAG production is the synthesis of DAG by a 
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phosphatidic acid hydrolase from phosphatidic acid. A third way to obtain 2-AG utilizes a 
phosphatidylinositol-preferring phospholipase A1 (PLA1), to obtain the lyso-PI 
intermediate, then a lysophosphatidylinositol-selective phospholipase C (lyso-PLC) 
catalyses 2-AG (Figure 18) [16]. However, the first pathway seems to be the most involved 
in the cannabinoid signalling.   
 
Figure 18. Biosynthetic pathways of 2-AG. 
 
After the activation of CB-receptors, a specific carrier-based uptake system transports the 
endocannabinoids into cells, where degradative enzymes inactivate them: FAAH in the 
postsynaptic neuron, MAGL in the presynaptic neuron, and two recently discovered 
enzymes, ABDH6 in postsynaptic neuron, and ABDH12 in the microglia (Figure 19). 
Anandamide is hydrolysed by FAAH (Fatty acid amide hydrolase), an amidase-signature 
enzyme, which acts also in the metabolism of non-cannabinoid fatty acyl ethanolamides 
(such as PEA). The hydrolysis of AEA leads to obtain free ethanolamide and arachidonic 
acid, but other metabolic pathways can support the inactivation of this cannabinoid. For 
example are involved in the anandamide degradation the enzyme COX-2, which furnishes 
prostaglandin E2-ethanolamide, the enzymes Lipoxygenases and cytochrome P450, which 
convert AEA into biologically active metabolites [17]. For what concern 2-AG metabolism, 
MAGL is the most important acting enzyme, realising arachidonic acid and glycerol. In 
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general, this serine hydrolase converts 2- and 1-monoglycerides into fatty acids and 
glycerol. In addition to MAGL other enzymes seems to be involved in 2-AG degradation, 
such as α-β hydrolase domain (ABHD-12 and ABHD-6), with the formation of arachidonic 
acid and glycerol. Cyclooxygenase-2 (COX-2) is involved too, furnishing multiple biologically 
active modulators, such as prostaglandin E2 glycerol ester (PGE2-G), and other 
prostaglandins.  
 
 
 
Figure 19. Overview of the endocannabinoid system.  
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1.2.2. MAGL: crystal structure and mechanism of action 
 
Monoacylglycerol lipase is a dimer, consisted of 303 amino acids, in rat, mouse and human 
forms, with a molecular weight of ~33 kDa. MAGL belongs to the α/β hydrolase 
superfamily, characterized by an eight-stranded β-sheet, consisted of seven parallel and 
one antiparallel strands, surrounded by α helices. The proteins of this family are variable in 
the structural portion named lid or cap domain, which in MAGL is necessary to the 
protection of the β-sheet conserved part and to shape the access of substrate to the 
catalytic site. For what concern MAGL crystal structure, two independent research group 
(PDB: 3JW8, Bertrand et al., 2010 [18]; PDB: 3HJU, Labar et al., 2010 [19]) have developed 
studies, both leading to two protein molecules per asymmetric unit. MAGL, respect of the 
other hydrolases (helices α1, α2, α3, α6, α7 and α8) is characterized by two additional 
helices, α4 and α5, contained in the lid variable domain, which results to be more 
hydrophobic. The active site, opposite to the phospholipid membrane, consists of a 
catalytic triad (Ser122, Asp239 and His269), buried below the cap domain. In detail, Ser122 
is located in the GXSXG consensus motif, between helix α3 and β5, also called “nucleophilic 
elbow”. The triad is necessary to maximize the nucleophilic character of Ser122, forming 
hydrogen-bonds system with Asp239 and His269. The three residues are accommodated 
at the bottom of a long channel, defined by hydrophobic residues (Leu148, Ala164, Leu176, 
Ile179, Leu205, Val207, Ile211, Leu213, Leu214, Val217, Leu241), interacting with the 
arachidonoyl chain of the substrate 2-AG. The channel is characterized by a U-shaped 
access. The active site is then connected to the outside of the enzyme by a small opening 
(~5Å), delimited by the cap domain. This hole is probably involved in the exit of glycerol, 
released after hydrolysis of 2-AG and the delimiting residues are Pro178, Ser181, Leu184, 
Tyr194, Asn195, Arg202, and Ala203. Another fundamental part is the oxyanion hole, 
constituted by the NH groups of Ala51 and Met123, on the loop linking α1 and β3, to 
stabilize the hydrolysis process, during the anionic transition state. Beside this hole, Tyr58 
hydroxyl group, the imidazolic NH groups of His121 and 272, the guanidinium of Arg57, the 
carboxylate of Glu53 and the carbonyl from Ala51 outline a polar fissure, necessary to 
interact with the glycerol part of 2-AG. 
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Figure 20. MAGL crystal structure and interactions of 2-AG. A) Arachidonoyl binding site, 
B) Oxyanion hole, C) Glycerol exit channel [19]. 
 
In the helix α4, three additional hydrophilic residues (Asn152, Glu154 and Lys160) might 
favour the interaction of MAGL with the hydrophilic part of 2-AG and the positively charged 
Lys160 is able to cooperate with the phosphate groups of membrane phospholipids. 
Furthermore, MAGL contains one sulfhydryl-sensitive site, important for the enzymatic 
activity; in particular, Cys242 is needed for substrate recognition, binding and enzymatic 
processing, but also Cys201 and Cys208 have a fundamental role. Two cysteine residues 
(Cys208 and Cys242) are in close contact with the catalytic site, while Cys33 is situated on 
β strands, inside of the hydrolase core, and Cys201 in the loop, connecting α5 and α6 
helices. The studies of different MAGL crystal structures exhibited various conformations 
of the lid domain, showing that its opening regulates the access of 2-AG to the enzyme. In 
fact, during the substrate interaction, helix α4 might close the active site access, leading to 
the dissociation of the enzyme from the membrane. Then MAGL assumes again an open 
conformation, re-associating with the membrane, after substrate cleavage, with the 
simultaneous conformational rearrangement of the lid domain [20]. Therefore, the enzyme 
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exists in two main conformational states: closed and open forms. MAGL exhibits its activity 
in the common mechanism of other serine hydrolase (Figure 21). The binding stage is the 
interaction with the water-lipid interface, where the protein disclose the access of the 
hydrophobic binding site, interacting with lipid droplet. This phenomenon has been called 
“interfacial activation”. The interaction with the substrate is due to an initial protonation 
of His269, of the catalytic site, from Ser122. The negative charge of Asp239 stabilizes 
histidine, leading to an enhanced nucleophilic character of the serine hydroxyl group, to 
attach the carbonyl carbon of the substrate. In this step, the formation of a tetrahedral 
intermediate occurs, and it is stabilized by the oxyanion hole. The following step is the 
acylation of the Ser122 and the elimination of the leaving group. Finally, a water molecule 
attacks the active site, leading to release of the product and to the initial conformation of 
the enzyme [22]. 
 
 
 
Figure 21. General catalytic mechanism of serine hydrolases [22].  
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1.2.3. MAGL: a pharmaceutical target 
 
It is not in the context of endocannabinoid system, but many years before, during the 
investigation of the pathways that govern lipid metabolism, that MAGL was brought to 
light. Several studies demonstrated the presence, in the adipocyte, of two proteins 
involved in lipolysis and distinct from the lipoprotein lipase (enzyme implicated in 
hydrolysis of triglycerides, derived from lipoprotein VLDL). These two proteins were HSL 
(hormone sensitive lipase), responsible of the conversion of triacylglicerols to 
monoacylglycerols, and MAGL, which completes the hydrolysis process, realising free fatty 
acids. Another enzyme, ATGL (adipose tissue triacylglycerol lipase) was then identified, as 
the effective hydrolase, converting TAG (triacylglycerol) to DAG (diacylglycerol), while HSL 
was discovered to be the responsible of DAG to MAG transformation [21]. Since its first 
identification in the adipose tissue, MAGL localization has extended to other tissues and 
now it is known to constitute a ubiquitously expressed enzyme. In the rat, high levels of 
MAGL mRNA are found in kidney and testis. In the brain, MAGL transcript is also present; 
despite lower mRNA levels are found in the brainstem and hypothalamus. A more detailed 
characterization of the anatomic distribution of MAGL and FAAH showed that the enzymes 
are complementary and they are situated in distinct neuronal compartments. Those areas 
are also characterized by high expression of CB1 receptors. In the adipocyte, MAGL was 
found in both membrane and cytosol, in the form of large lipid-containing aggregates, and 
it behaves as a selective 2-monoacylglycerol hydrolase, to complete the hydrolysis of 
triacylglycerols. Therefore, besides its original role in the mobilization of fat, which led to 
its discovery in the early sixties, MAGL acts also in the metabolism of 2-
arachidonoylglycerol, which is involved as a key messenger of the endocannabinoid system. 
2-AG hydrolysis releases arachidonic acid, the major precursor for the synthesis of pro-
inflammatory eicosanoids in specific tissues, such as the brain, liver, and lung. 
Endocannabinoids are generally produced in response to injury, because of their beneficial 
action in decreasing pro-inflammatory mediators and re-establishing homeostasis. MAGL 
inhibition increases the levels of 2-arachidonoylglycerol in the brain, interacting with the 
cannabinoid receptors to decrease pain and inflammation process, with a lower production 
of arachidonic acid. It is well established that inflammation is also a component of several 
neurodegenerative diseases like Parkinson and Alzheimer, where prostaglandins, derived 
from metabolites of 2-AG by MAGL, are the most important mediators in these responses. 
Indeed, genetic and pharmacological block of MAGL exhibit anti-inflammatory effects in 
the brain and neuroprotective effects in mouse models of Parkinson's disease and 
Alzheimer's disease. There is a low cannabinoid component in the protective response seen 
with MAGL inhibitors in these models; this can be connected to the functional 
desensitization of the cannabinoid system over chronic MAGL blockade. In addition, the 
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anti-inflammatory properties of cannabinoids are associated with a decreased number of 
activated microglia and other immune cells.  Invading the nervous system, they are 
responsible of the release of toxic cytokines and free radicals in multiple sclerosis, which 
represents a big portion of the neurodegenerative damages. For what concern the role of 
MAGL in cancer, is important to considerate that the conversion of cells, from a normal to 
cancerous state, involves the alteration of metabolic pathways, including the regulation of 
glycolysis, glutamine dependent anaplerosis and the development of a lipogenic 
phenotype. Indeed, de novo lipid biosynthesis has been posited to play a major role in 
cancer, where, in detail, FAS (Fatty acid synthase) drives lipogenesis. This enzyme is 
responsible of fatty acid biosynthesis, from acetate and malonyl CoA, fundamental for 
survival and proliferation of cells, via fatty acid oxidation and it is correlated with poor 
prognosis in breast cancer patients. Other features of lipid biochemistry are involved in the 
malignancy development of cells: the formation of building blocks for newly synthesized 
membranes, to support high rate of proliferations [23]; the composition and regulation of 
membrane structure, fundamental for signal transduction and motility [24]; the biosynthesis 
of an array of pro-tumorigenic lipid signalling molecules [25].  Many lipid are important for 
the contribute to cancer: phosphatidylinositol-3,4,5-trisphosphate [PI(3,4,5)P3], which 
activates protein kinase B/Akt to promote cell proliferation and survival; lysophosphatidic 
acid (LPA), which signals stimulate cancer aggressiveness through G-protein coupled 
receptors; and prostaglandins formed by cyclooxygenases, which support migration and 
tumor-host interactions. Cancer cells also necessitates of a complementary lipolytic 
activity, to liberate stored fatty acids (incorporated into neutral and phospholipids), 
indispensable for metabolic and signalling functions. Lipolysis process is due to MAGL, 
overexpressed in many tumours, both in aggressive and non-aggressive cancer cells, but 
the pathways that regulate lipolysis in cancer cells remain poorly understood. MAGL 
catalyses the hydrolysis of monoglycerols, from stored triacylglycerols, to generate free 
fatty acids (FFAs) and glycerol, and promotes migration, survival and tumour growth. The 
blockade of MAGL produces significant elevations in the levels of several MAGs, including 
2-AG, in aggressive cancer cell lines; furthermore, it also causes significant reductions in 
the levels of FFAs [26]. This is in contrasts with the function of MAGL in normal tissues, where 
in general, the enzyme does not control the levels of FFAs. In tumours, MAGL is involved in 
the action of the increased fatty acids, especially C16:0 or C18:1, as precursors of 
lysophospholipids (such as LPA) and eicosanoids (such as PGE2), which operated as pro-
tumorigenic lipid signalling molecules. Moreover, it was seen that the defacement in the 
MAGL-FFA pathway is rescued by exogenous fatty acids. In particular, a high-fat diet can 
contribute to malignancy in cancer cells, lacking MAGL activity, showing a correlation 
between obesity and tumorigenesis. In addition, also the endocannabinoids seem to have 
a role as anticancer compounds, against cells growth and aggressiveness, considering the 
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overexpression of CB1 receptors in several tumours. While in ovarian, breast and melanoma 
cancer cells MAGL inhibition exerts an anti-tumorigenic effect, through the reduction of 
oncogenic signalling lipids. In prostate cancer cells MAGL blockade-dependent anti-cancer 
effects are mediated by both enhanced CB1 signalling and impaired lipid network. 
Moreover, MAGL inhibition is responsible for the downregulation of cyclin D1 and Bcl-2, 
involved in colorectal cancer pathogenesis [27]. Despite this, the lack of effect of cannabinoid 
receptor antagonists on migration, indicates that the stimulated cancer aggressiveness 
mechanism of MAGL involves the action of FFA-derived products, rather than reductions in 
MAGL substrates, such as the endocannabinoid 2-AG [26]. All these considerations lead to 
understand the several functions of MAGL in carcinogenesis, inflammation and 
neurodegenerative diseases. For these reasons, the enzyme is a potential therapeutic 
target, manipulating endocannabinoid, eicosanoid, and other lipid signalling pathways (Figure 
22).  
 
Figure 22. Several functions of MAGL and effects of its inhibition. [28] 
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1.2.4. MAGL: background of the inhibitors 
 
In general, the covalently bound MAGL inhibitors act on two different sites of the enzyme: 
the cysteine residues and the nucleophilic serine of the catalytic site.  First inhibitors of 
MAGL were described forty years ago and comprise several sulfhydryl-reacting compounds, 
including p-chloromercuribenzoate (pCMB), mercurichloride (HgCl2) and N-ethylmaleimide 
(NEM). In fact, the experimental studies on MAGL active site showed the presence of 
cysteines (Cys201, Cys208 and Cys242); therefore, these evidences led to the development 
of N-arachidonylmaleimide (NAM), the most potent compound using this scaffold, with an 
IC50 value of 0.14µM on rat cerebellar membranes [21]. Since NAM is a Michael acceptor, it 
acts as an irreversible MAGL inhibitor, by the Michael addiction of the 
arachidonoylmaleimide group to Cys201 and Cys242. Other cysteine-targeting compounds 
are Disulfiram, disulfiram derivatives and phenyl disulphide, tested to investigate the role 
of cysteine residues in the modulation of MAGL activity. Disulfiram was already known as 
a treatment against alcoholism, but the compound also inhibits MAGL with a micromolar 
affinity (6.87 ± 0.05 µM) [29]. On the base of this template a potent developed derivative 
was bis(4-methyl-1-piperazinylthiocarbonyl) disulphide, which displayed an IC50 of 110 
nM on the pure enzyme, and a more than 1000 selectivity ratio for MAGL compared to 
FAAH [21]. This compound exhibits MAGL inhibition through a redox mechanism, involving 
the sulfhydryl groups of Cys208 and Cys242. During the investigation of a series of 
sulfhydryl-reactive agents, it was developed another compound, able to inhibit the rat 
MAGL: the 2-octyl-isothiazol-3-one (Octhilinone, IC50 = 88 nM) [21]. The molecule inhibits 
the enzyme through a partially reversible mechanism, with the formation of a disulphide 
bond between the sulphenamide group and a cysteine residue of the protein. Besides this, 
Pristimerin and Euphol, two natural terpenoids, were identified as inhibitors of rat MAGL 
(IC50 on rat MAGL: primisterin, 93 nM; euphol, 315 nM) [21]. Most interestingly, these 
compounds act through a reversible mechanism, by interacting with either Cys201 or 
Cys208. 
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Figure 23. Cysteine-targeting compounds. 
 
Other compounds interacts with the nucleophilic Serine122, in MAGL catalytic site. The first 
characterization of MAGL identified trifluoromethylketones as inhibitors, such as 
arachidonoyltrifluoromethylketone (ATFMK), and the irreversible inhibitor 
methylarachidonylfluorophosphonate (MAFP). Despite the fact that the voluminous and 
lipophilic arachidonyl chain would be likely to provide MAFP and ATFMK an improved 
selectivity profile versus proteins belonging to other systems, these compounds also 
displayed several off-targets. MAFP was first reported as a phospholipase A2 inhibitor and 
inhibits FAAH and MAGL with similar potencies, while ATFMK acts on MAGL, FAAH and CB1 
cannabinoid receptor. In addition, a series of trifluoromethylketones with a β-thioether 
moiety were developed, among which octylthiotrifluoropropan-2-one (OTFP) increased 2-
AG levels. However, the trifluoromethylketone scaffold constitutes an unselective portion 
for MAGL inhibition; in fact, these compounds are potent against other esterases, such as 
FAAH, also because of their similarity in the substrate structure.  
 
 
Figure 24. First Serine-targeting compounds. 
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One of the first MAGL-preferring reversible inhibitors was URB602, an O-biphenyl 
carbamate (Figure 25) with an IC50 of 223 µM. Although the potency of the molecule is not 
high, it leads to the selective accumulation of 2-AG, but not anandamide. URB602 enhances 
CB1 receptor-mediated stress-induced analgesia; moreover, it exerts peripherally mediated 
antinociceptive effects, in the case of inflammatory and neuropathic pain. URB602 inhibits 
rat MAGL through a non-competitive mechanism; further work demonstrated that the 
inhibition is time-independent and that this molecule does not mimic the substrate [30]. 
Unfortunately, URB602 exhibits a similar potency in the inhibition of MAGL and FAAH. 
Several modification to its structure were applied, including isosteric replacements, ring 
size and substitution, para-substitution of the biphenyl moiety and the incorporation of a 
bicyclic element. Furthermore, the ureidic analogues of URB602 maintained moderate 
MAGL inhibition activity, showing that the carbamate and the urea functionalities were 
promising scaffolds for the development of inhibitors. 
 
Figure 25. Structure of URB602. 
 
Other carbamates that lead to MAGL inhibition include SPB01403 (IC50 = 31 µM on rat 
cerebellar membranes), and CAY10499 (IC50 = 0.5 µM to 20 nM on the pure human MAGL, 
depending on the preincubation time) [21]. However, also these compounds are unselective, 
with the inactivation of FAAH. 
 
 
 
Figure 26. Structure of CAY10499 and SPB01403. 
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One of the most promising progress, in the achievement of selective MAGL inhibitors, was 
the development of carbamate derivatives, by Cravatt’s team [31]. The low nanomolar 
inhibitor JZL184 was one of the most important compound, which exhibits an IC50 of 8nM 
for MAGL and a comfortable selectivity versus FAAH in vitro (IC50 = 4 µM) [20]. Other 
exponents of the 4-nitrophenyl carbamates are rather promiscuous, as shown by the 
FAAH/MAGL dual inhibitor, JZL195.  
 
 
Figure 27. Structure of the 4-nitrophenyl carbamates, JZL184 and JZL195. 
 
The inhibition mechanism of JZL184 involves the carbamoylation of the Ser122, with the 
p-nitrophenol as the leaving group; the resulting complex is stable against hydrolysis, and 
is responsible for irreversible inhibition of the enzyme. 
 
Figure 28. Mechanism of MAGL inhibition by JZL184 
 
As expected, the blocks of MAGL in vivo causes a considerable increase of 2-AG levels in 
the brain. The accumulation of 2-AG is accompanied by a strong CB1-dependent analgesic 
effect in different models of nociception. However, this pharmacological blockade leads to 
desensitization and cross-tolerance to CB1 receptor agonists. A possibility is the use of low-
doses of JZL184, causing anxiolytic effects, also manteined after chronic treatment. 
Another chance is the use of an intermittent dosage, to reduce neuroinflammation and 
degeneration, with the enhancement of cognitive function in animal model of Alzheimer’s 
disease. Despite this, the labilities of the molecule impedes its clinical development, 
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limiting its use as an experimental reference for MAGL inhibition. New compounds with O-
hexafluoroisopropyl carbamate or N-hydroxysuccinimidyl carbamate functionalities have 
been studied. KML29 is an analogue of JZL184, characterized by the substitution of the p-
nitrophenyl leaving group with a hexafluoroisopropyl. The introduction of a bioisosteric 
moiety, able to mimic the polar glycerol head of the endogenous substrate 2-AG, 
apparently leads to a complete selectivity for MAGL over FAAH and other brain hydrolases. 
Another interesting compound was SAR127303, a potent O-hexafluoroisopropyl 
carbamate. This compound is characterized by the same leaving group and piperidine 
carbamate functionalities as KML29, but it presents a different substituent at the piperidine 
ring. SAR127303 is a potent inhibitor of mouse and human MAGL (IC50 = 3.8 nM and 29nM 
respectively) and shows high selectivity for MAGL over other human hydrolases [32]. The 
molecule exerts antinociceptive and antiepileptic effects in inflammatory and visceral pain 
models. However, it negatively affects memory formation, leading to impaired cognitive 
performance in spatial, episodic and working memory. A piperidine or piperazine ring 
composes other selective inhibitors of MAGL, with a serine-carbamoylating functionality 
including triazoleurea.  In the case of JJKK-048, the 1,2,4-triazole moiety conducted to one 
of the most selective irreversible MAGL inhibitors. 
 
 
      
Figure 29. Structure of KML29, SAR127303 and JJKK-048. 
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2.1 Introduction to the experimental section 
The first part of the project research of my thesis work has concerned studies about nitro 
aromatic Hypoxia-activated prodrugs (HAP), with the aims of inhibiting Lysyl Oxidase, 
realising BAPN (pro-BAPN). In general, hypoxia activated prodrugs are characterized by two 
or three functional components:  
- a trigger, sensible to the reducing environment, which is activated in these 
conditions; 
- an effector, the real cytotoxic drug; 
- an optional linker, able to pass down the activation from the trigger to the effector. 
In the case of KS119 (Chapter 1, page 15) the nitro-benzyl group is the trigger, the 
carbamate is the linker, and the hydrazine alkylating warhead is the effector (Figure 30). 
 
Figure 30. Example of functional components in the case of KS119. 
 
2.1.1 Consideration for HAP design 
Some considerations are fundamental for the design of HAP. First an appropriate one-
electron reduction potential is important for the therapeutic selective effect between 
hypoxic and normoxic cells. If the reduction potential was too low (as in the case of the 
mono-nitro substituted phenyl compound, E1= -486 mV) the activation would be impeded, 
however if it was too high the reducing process would be too fast. For this reason, some 
modifications can be adopted to maintaining the empirical range of the reduction potential 
between -450 and -300 mV [33,34], to avoid the potential toxicity. The addition of electron-
withdrawing substituents into a mono-nitro benzene trigger is a possibility for enhance the 
reduction potential. Another strategy is the substitution of nitro benzene with other nitro 
heterocycle, such as nitrofuran, nitroimidazole, nitrotiophene. In the case of Evofosfamide 
(TH302, Figure 31) the introduction of the nitroimidazole as the trigger leads to a reduction 
potential E1= -407 mV [35].  
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Figure 31. Structure of Evofosfamide.  
Another consideration for HAP design is the ability to diffuse in tissues and the stability of 
the prodrug. In fact, passive diffusion is the principle form of transportation into the cell, 
and it is primarily influenced by the compound’s lipophilicity (log P, octanol/water partition 
coefficient), furthermore the diffusion of larger molecules is markedly reduced. For what 
concern the stability of the compounds, a steady molecule is not activated even in hypoxic 
conditions, whereas a high metabolism causes a prematurely activation of the prodrug. In 
addition, the stability and the diffusion of the activated effector are fundamental, 
influencing the level of the bystander effect.  In conclusion, a five-atom nitroaromatic 
trigger, joined to the right level of lipophilicity and stability of the molecule, produces a 
suitable condition for the development of HAP. Furthermore, adopting a linker in the HAP 
design, as a carbamate, is useful for the attachment of the bioreductive functionality to a 
poor leaving group. In fact, its ability influences the fragmentation process, once the nitro 
group has been reduced. 
2.1.2 Pro-BAPN previously synthesized 
With regard to the consideration about HAP design, described above, the research group, 
where I performed my thesis work, synthesized some nitroaryl pro-drugs of BAPN. These 
molecules are nitrobenzyl- (2.1, 2.2), nitrobenzylcarbonyl- (2.3) and nitrofuranmethyl- (2.4) 
derivatives of BAPN, where a methyl and a methoxycarbonyl group are used as linker.  
 
 
Figure 32. Structures of Pro-BAPNs, previously synthesized. 
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The mechanism of action of the Pro-BAPNs is explained in Chapter 1 (page 13). Considering 
that the bioreductive activation of HAP is related to reduction potential values, the 
synthesized compounds were analysed, using cycle voltammetry, in iso-osmotic saline 
phosphate buffer solutions, at pH 7.2 (Figure 33). Scanning the potential from 0.0 to 1.8 V 
the voltammogram indicated a single peak for each compound, as the result of the 
reduction of the nitro group to hydroxylamine; furthermore, the lack of an oxidation peak 
suggested an irreversible reduction process in the NO2/NHOH conversion. The reduction 
potential E0 of the compounds 2.1 and 2.3 was similar, in the range of -0.75 V, while 
compound 2.2 and 2.4 displayed respectively -0.77 and -0.61 V. Compound 2.4 turned out 
to be the most easy to reduce, therefore its activation in hypoxic conditions is preferred.[36] 
 
 
Figure 33. Cyclic voltammograms of compounds 2.1-2.4. Measurements were recorded, 
using 5.10-4 M solutions, at glassy carbon electrode in phosphate buffer (pH 7.2, 0.15 M 
NaCl), with a sweep rate of 0.1 Vs–1. Compound 2.4 in blue; 2.3 in red; 2.2 in yellow; 2.1 in 
green, in the graph. 
 
 
Compounds 2.1-2.4 were then submitted to biological assays, by the research group of 
Prof. Amato J. Giaccia at the University of Stanford (California, USA). The first assay 
provided for the measuring of the fluorescent activity, correlated to the LOX inhibition. In 
fact, a decrease of fluorescence indicated a reduction on LOX activity. The assay was 
realized in conditioned medium (CM) from hypoxic MDA-MB-231 breast cancer cells, 
incubated with BAPN (200 µM), in hypoxic and normoxic conditions [37]. Compound 2.2 gave 
a high level of fluorescence, but this unexpected result is connected to the high 
photolability of the molecule, reason why this value was excluded (Figure 34). The other 
three compounds resulted more active in hypoxic conditions, index of their reductive 
activation; moreover, 2.3 and 2.4 furnished the best results as LOX inhibitors [36]. 
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Figure 34. LOX inhibition fluorescence assay for LOX activity on CM from MDA-MB-231 
cells incubated in air or hypoxia (2% O2) with 200 μM LOX inhibitors 2.1-2.4. 
 
The second test consisted of the in vitro invasion assay, incubating MDA-MB-231 breast 
cancer cells in the same conditions of the previous assay [38]. This assay was necessary to 
observe the anti-invasion abilities of the compounds. In the control data the cancer cell line 
resulted to be more aggressive under hypoxic conditions, furthermore the best results 
were obtained with compound 2.3 and 2.4, again (Figure 35). In the case of the nitrofuran 
2.4 the level of invasion was certainly reduced in hypoxia, whereas in oxygenated situation 
the invasion was similar to the control data. This evidenced that compound 2.4 had hypoxia 
selective agent characteristics, while 2.3 showed low level of invasion also in normoxic 
environment, probably by a non-LOX-mediated mechanism.  For this reason, it was 
considered a non-selective compound for hypoxia [36]. 
 
 
Figure 35. Cell invasion assay to test ability of the compounds 2.1-2.4 to inhibit in vitro 
invasion of MDA MB-231 cells incubated in air or hypoxia (2% O2) with 200 μM LOX 
inhibitors. 
 
The described data indicated a hypoxia enhanced activities in the case of compound 2.4, 
due to the nitrofuran moiety, which is easier activated than the nitrobenzyl moieties of 
compound 2.1-2.3. Part of the biological activity of these compounds may be related to an 
action of the trigger, after detaching from BAPN, but this theory remains unproved. These 
studies showed that the use of nitroaromatic pro-drugs, selectively to inhibit LOX, is a 
possible way to reduce or block the invasiveness of hypoxic tumours. The use of different 
masking moieties, linked to BAPN, is a research line, which can be developed. For this 
reason, during my thesis project, others nitroaromatic pro-BAPNs were synthesized, 
considering that the nitrofuran portion seemed to be selective for hypoxic tumour tissues, 
limiting the undesired side effect of the BAPN.  
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2.2. Results and discussion  
The first part of my thesis work was dedicated to the synthesis of two compounds, which 
can be useful as hypoxia-activated-prodrugs (HAP). In particular, in a hypoxic environment, 
they can release BAPN (β-aminopropanenitrile), as the active drug, which is a direct 
inhibitor of lysyl oxidase (LOX). The selection of these structures was based on previous 
studies, of several masking groups of BAPN. In fact, the use of nitro-aryl precursors is the 
most popular approach for the synthesis of HAP.  The importance to obtain these two 
compounds is manly found in the study of the comparison of the effects given by the two 
different aromatic heterocycles that are used as triggers: 1-methyl-2-nitroimidazole, and 
4-nitrotiophene.  
 
 
 
 
                                               
Figure 36. Structures of compounds synthesized in my thesis work. 
 
 
 
 
 
 
 
1 
2 
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2.2.1. Synthesis of compounds 1 and 2 
 
 
Scheme 1. Synthesis of compounds 1 and 2. 
The synthesis of these two compounds is characterized by an initial condensation between 
the aldehyde of the aromatic ring and the amino-group of BAPN, followed by the reduction 
of the imine intermediate to amine, using NaBH4 (Scheme 1). The final step consists of a 
treatment with Et2O.HCl. In detail, the steps used to obtain the amine products 5a-b are a 
reductive amination, in which the amino group of BAPN attaches the carbonyl carbon of 
the initial aldehyde, then the imine is reduced by NaBH4. The mechanism of this 
condensation is explained in the scheme below (Scheme 2) [39]. 
Chapter 2   LOX inhibitors 
|38 
 
 
 
Scheme 2. Mechanism of condensation with BAPN. 
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We used different conditions to obtain the nitro-imidazole compound 1, and the nitro-
tiophene 2. During the synthesis of 1 we followed the classic procedure (Scheme 1), 
employing BAPN in dry DCM for 16 h. In the synthesis of 2 we applied some modifications, 
because the normal conditions (Way a, Table 1) did not lead to the desired molecule, and 
we could observe a sort of dark precipitate that we described to a polymerization during 
the formation of imine.  Initially (Way b, Table 1) we tried to change the solvent, using dry 
MeOH, and after 16 h, we have continued in situ, with the next step of reduction with 
NaBH4.  In fact, in this consecutive reaction, MeOH is common employed as solvent, so we 
did not have to add it. Unfortunately, the modified procedure was unsuccessful, so we tried 
to reduce the time of condensation with BAPN. After only 2 hours we stopped the reaction 
(Way c, Table 1), proceeding with the addition of NaBH4 directly in situ. This final tentative 
produced the wanted compound 5b, and the following reaction of precipitation led to the 
final compound 2. In conclusion, a long-time of reaction, during the formation of the imine 
intermediate, probably caused the polymerizations, which got more difficult to obtain the 
wanted compound 2. 
 
Table 1. Reagents and conditions of synthetic attempts for compound 5b. 
 Reagents and 
temperature 
 
Solvent Time Results 
Way a 
 
BAPN, RT Dry DCM 16h Polymerization 
Way b BAPN, RT,  
“one pot” 
procedure 
Dry MeOH 16h Polymerization 
Way c BAPN, RT,  
“one pot” 
procedure 
Dry MeOH 2h Final product 
5b 
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2.2.2. Synthesis of compound 3a 
 
With regard to the synthesis of compound 1 the corresponding starting aldehyde, the 
compound 3a, is not commercially available, reason why we decided to synthetize it during 
my thesis work (Scheme 3).         
  
 
Scheme 3. Synthesis of compound 3a. 
a) NaH, THF, ethyl formate, RT, 3h. 
b) EtOH, HCl conc., 105 °C, 2h. 
c) NH2CN, EtOH, H2O, 120 °C, 1,5h. 
d) NaNO2 aq., CH3COOH, RT, 4h. 
e) NaBH4, THF, MeOH dry, 0 °C, 5 min, RT, 1h. 
f) MnO2, DCM dry, RT, 3d. 
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In order to obtain this compound, we followed a synthetic procedure reported in literature 
[40]. This synthetic procedure was based on the work of Matteucci et al, but it was emploied 
sarcosine ethyl ester hydrochloride (instead of methyl ester) as the starting material, and 
THF as co-solvent along with ethyl formate, to enhance the solubility of the sarcosine. 
Below the procedure of O’Connor, L.J. et al. is described, including some modifications we 
decided to adopt, to optimize the most critical synthetic steps. The first step of this 
synthesis is a double formylation on the sarcosine ethyl ester hydrochloride, using ethyl 
formate, and NaH as the base, in THF.  The second step consists of a de-formylation on the 
N-atom of the formylated sarcosine intermediate (compound 7), conducted in acidic EtOH, 
by heating under reflux. In the following reaction, the presumed solid intermediate 8 was 
treated with cyanamide, under reflux in aqueous 70% EtOH, to give the addition on the 
carbonyl carbon of the formylated group, and obtain the wanted aromatic cycle 2-
aminoimidazole (compound 9). To minimise ester hydrolysis, the reaction solution was 
adjusted to pH 3–4 using 2 M aqueous NaOH. In our work, we did not isolate intermediate 
8, but we decided to proceed in situ with the following reaction of cyclization. Initially we 
introduced the nitro functionality via diazotisation of the amino group, adding a solution of 
9 in CH3COOH, in a drop wise manner via a syringe, to an aqueous solution of NaNO2, 
following the original procedure. This step consists of the generation of nitrous acid in situ, 
losing water molecule to give nitrosyl cation NO+ (Scheme 4). This cation is then transferred 
to the amine, to obtain the relative diazonium salt, unstable in aqueous solution at 
temperature above 5 °C (the reaction was performed at -5/-10 °C), then the N2+ group is 
lost as N2 [41]. The consecutive nitration allows to obtain the 2-nitroimidazole, product 10 
with a low yield (30%). 
 
Scheme 4. Mechanism of the diazotization-nitration. 
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To improve the yield of this step we tried to add the aqueous solution of NaNO2, earlier 
prepared, to a flask containing compound 9 in CH3COOH. This procedure did not give the 
wanted product. The last attempt consisted in anticipating the reduction step (reaction e, 
Scheme 3), with the aim to obtain compound 11, by reducing the ethyl ester of compound 
9 and then try the diazotization-nitration method on this intermediate, to give compound 
12, but unfortunately we could not obtain compound 11. Therefore, we decided to reduce 
compound 10. In fact, the 2-nitroimidazole 10 is treated with NaBH4, in THF and MeOH, at 
0 °C, to reduce the ethyl ester group to hydroxyl (compound 12). The next reaction of the 
protocol consists of an oxidation of 12, using MnO2 in dry DCM, to give the aldehyde group, 
necessary to the final three steps, to obtain 1. The final products have been submitted to 
the VU Amsterdam, where they will be analysed by Dr. Elisa Giovannetti, to evaluate LOX 
inhibition and antiproliferative assays. The obtained results will show how the two different 
aromatic heterocycles, used as triggers, might influence LOX activity.  
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3.1. Introduction to the experimental section 
 
The second part of my thesis project dealt with the development of reversible 
monoacylglicerol lipase inhibitors. In fact, the molecules, which interact with this enzyme, 
are classified in three categories: 1) irreversible and covalently bound, 2) reversible and 
covalently bound, 3) non-covalently bound. The first two classes are able to bind the serine 
122 of the MAGL catalytic site, but several molecules are not selective, and interact also 
with FAAH enzyme. An irreversible and selective compound for MAGL versus FAAH is JZL-
184 that was synthesized by Cravatt et al. [31], and it was used as a reference inhibitor in 
the consecutive experimental developments. The substitution of the 4-nitrophenyl 
carbamate with a 1,2,4-triazole moiety conducted to one of the most selective irreversible 
MAGL inhibitors, compound JJKK-048, characterized by a urea-type functional group 
(Figure 37). 
                
 
 
Figure 37.  Structure of JZL-184 and JJKK-048. 
 
Considering these results, a general structure for MAGL inhibitors, covalently bound to the 
catalytic site, can be represented. In fact, the classic MAGL inhibitors are constituted by a 
lipophilic scaffold, connected to a heterocyclic aromatic system by an eventual linker. In 
the case of the MAGL inhibitor CAY10499  [47], the 5-methoxy-1,3,4-oxadiazol-2(3H)-one 
ring is the polar heterocycle system, linked with the methylphenyl group to the lipophilic 
benzyl carbamate. 
 
 
 
Figure 38. Structure of CAY10499. 
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3.1.1.     The 4-aryliden-2-methyloxazol-5(4H)-one scaffold 
The 5-methoxy-1,3,4-oxadiazol-2(3H)-one ring of CAY10499 is an important moiety, able 
to inhibit MAGL with the carbonyl atom of the oxadiazolone, attacking the hydroxyl group 
of the Serine 122 of the catalytic region. In the research group, where I performed my thesis 
work, a similar cyclic structure was developed, that is a 2-methyl-4-methylenoxazol-5(4H)-
one scaffold. In this moiety the central cycle is a lactone and the 4-arylidene portions is 
inserted to mimic the C-N bond of the 5-methoxy-1,3,4-oxadiazol-2(3H)-one (Figure 39) [42].  
 
Figure 39. Design of the 2-methyl-4-methylenoxazol-5(4H)-one-based compounds. 
 
Docking studies in human MAGL, conducted in our department by Tiziano Tuccinardi and 
Adriano Martinelli, revealed the formation of two fundamental H-bonds in the catalytic 
site, by the oxygen of the carbonyl carbon of the oxazolone: the first with the OH group of 
Serine 122, the second with the NH2 group of Alanine 51 (Figure 40). These interactions 
were maintained, docking CAY10499 in the catalytic site, by the carbonyl carbon of the 
cycle carbamate. Docking studies into humanized-rat FAAH showed similar two H-bonds 
for CAY10499 in the catalytic site, with Serine 124 and Isoleucine 238, demonstrating a low 
selectivity for this compound.  On the contrary the 2-methyl-4-methylenoxazol-5(4H)-one 
did not interact with the catalytic Serine 124 and it showed a completely different 
disposition into FAAH. In fact, the oxazolone group is characterized by a Z-configuration, 
and this rigid geometry obstructs the access to the catalytic site of FAAH, promoting a high 
selective action for MAGL versus FAAH.  
 
 
Figure 40. H-bond interactions into MAGL catalytic site. 
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3.1.2.     Biphenylic derivative previously synthesized 
 
The research team had initially synthesized three different 2-methyloxazol-5(4H)-ones, 3.1, 
3.2, 3.3, substituted in position 4 (Figure 41). The 4-benzyliden derivative 3.1 turned out to 
be the most active for MAGL inhibitions (IC50=24.1 µM) and the most interesting, for what 
concern the selectivity against FAAH (>200 µM) [42]. 
 
 
Figure 41. 4-Aryliden-2-methyloxazol-5(4H)-ones. 
 
On the bases of these results, the consecutive developments were focused on the 
achievement of biphenylic derivatives, introducing on compound 3.1 a second 
unsubstituted or para-substitued aromatic ring in several positions, with three different 
substituents (Figure 42). 
 
 
 
Figure 42. Biphenylic derivatives. 
R: H, F, OCH3 
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These nine molecules were tested, analysing the inhibition activity (IC50) on human MAGL 
and FAAH (Figure 43). The range values of 1.0-2.2 µM on MAGL and 33.9-111 µM on FAAH 
showed a medium level of inhibition and a high selectivity for MAGL, comparable to JZL-
184; furthermore, these data did not express a marked difference on the base of the 
position of the second aromatic ring, or the substituent groups [42]. 
 
 
Figure 43. IC50 on human MAGL and FAAH of the analysed compounds. 
 
 Despite of this, the most selective molecule was the para-fluoro derivative of compound 
3.4, so the research group decided to further investigate its inhibition mechanism.  The first 
assay was performed (Figure 44) in the presence of 10 µM of DTT (thiol-containing agent 
1,4-dithio-DL-threitol) for 15 minutes, to evaluate an eventual interaction with the cysteine 
groups of MAGL, and it showed a similar IC50 in the absence or presence of DTT, shifting 
respectively from 1.7 µM to 2.0 µM. 
 
Figure 44. DTT assay of compound 3.4, para-fluoro substituted. 
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The compound was then subjected to a dilution assay, which has demonstrated its 
reversible inhibition (Figure 45). In fact, the third column of the histogram indicates that 
the inhibition level, after the dilution of the compound (to a final concentration of 1 µM) is 
considerably reduced, compared with the first column (inhibition produced by 40 µM of 
compound), whereas is similar to the second (concentration of 1 µM). 
 
 
 
Figure 45. Dilution assay of compound 3.4, para-fluoro substituted.  
 
The last assay consisted of a pre-incubation test, in which an irreversible bond with the 
enzyme shows an increase of the inhibition level, after longer incubation times. In this case 
the graphic demonstrates that after 30 and 60 minutes the inhibition of MAGL is constant, 
proving again it is a reversible inhibitor (Figure 46).  
 
 
 
 Figure 46. Pre-incubation assay of compound 3.4, para-fluoro substituted. 
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Successively, the three para-fluoro derivatives of compounds 3.4, 3.5, 3.6, were tested in 
vitro, in the antiproliferative assay, using four tumour cell lines, in which MAGL is over-
expressed: the human breast MDA-MB-231 and MCF-7 cells, the human ovarian COV318 
and OVCAR-3 cells (Figure 47).  
 
Figure 47. Cell growth inhibitory activities (IC50) of para-fluoro derivatives 3.4, 3.5, 3.6. 
 
All the compounds were active, with regards to JZL-184 and CAY10499; moreover, the 
better inhibition growth, in the ovarian cell lines, was given by the p-fluoro 3.4. 
Computational studies were then used to explain the interaction of these compounds with 
MAGL and FAAH binding site. The docking analysis of the 2-methyloxazolone ring was 
discussed above, but other functional groups were investigated. In fact, even though the 
benzylidene fragment is not involved in the interaction, its rule as linker is resulted 
fundamental to the insertion of the p-fluorophenyl portions into a lipophilic pocket.  This 
cavity of the enzyme is delimitated by the amino acidic residues M88, L176, G177, P178, 
I179 and L205. Compound 3.7 was then synthetized (Figure 48) and analysed, to 
understand the fundamental pharmacophoric portion of the previous molecules.  
 
 
Figure 48. Synthesis of compound 3.4. 
 
In MAGL and FAAH inhibition assays, this compound resulted to have a low activity (IC50 
>200 µM), in fact the hydrolysis of compound 3.6 led to a biphenylacetamidoacrylic acid 
derivative 3.7, which did not interact with the catalytic site of MAGL, because of the lack of 
the oxazolone ring.  
With the aim to expand the structures of compounds 3.4, 3.5 and 3.6 into the MAGL binding 
site that presents open lipophilic cavities, it was decided to attach another aromatic ring, 
in various positions of the common central benzene (Figure 49).  
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      CG-946-B     CG-964-B                               CG-968-B 
 
                              
      CG-974-B                                          CG-980-B 
 
Figure 49. Structures of terphenilic compounds, with the additional benzene in various 
positions. 
 
After biological evaluations of these five compounds (Chapter 4), the presence of the 
phenilic groups in position 2 and 5 of the central benzene (compound CG-980-B) resulted 
to give the best inhibition results. All these considerations had contributed to the 
development of new MAGL inhibitors during my thesis work. The aims of my research 
project was the synthesis of several terphenylic derivatives of compound CG-980-B, 
introducing some substitutions, to evaluate how these changes might influence the 
inhibitory activity.  
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3.2. Results and discussion  
 
In the second part of my thesis work I dealt with the synthesis of a different class of 
molecules, the inhibitors of MAGL. On the basis of previous studies, it was seen that 
compounds possessing a 4-aryliden-2-methyloxazol-5(4H)-one scaffold were selective 
reversible inhibitors. In detail, my assignment was the modification of the terphenylic 
group of oxazolone CG-980-B (Figure 50), introducing various substitutions in rings A and 
C.  
 
 
Figure 50. Modifications on the terphenilic oxazolone CG-980-B. 
 
In particular, the substituent groups were inserted in para (compound 13-16 and 20), 
meta (compound 17), or both positions (compound 18-19) of ring A and C. 
 
 
  
13 14 
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Figure 51. Structures of compounds synthesized in my thesis work. 
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In two cases (compound 21 and 22, Figure 52) the introduction of the hydroxyl and the 
cyano groups in the para position has not been possible. 
                       
 
 
Figure 52. Structures of compounds I try to synthetize in my thesis work.  
The obtained final products were only the isomers in Z-configuration, which are more 
thermodynamically stable then the (E) isomer. Actually, these molecules were sensible to 
the light, which can cause a photo-isomerization from (Z) to (E) isomers [43]. In fact, we 
needed to protect the compounds from the light by keeping them in the dark to avoid the 
formation of a mixture of Z and E-isomers.   
 
  
Figure 53. Photo-isomerization. 
 
  
21 22 
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3.2.1. Synthesis of compounds 13-20 
 
The synthesis of these compounds starts from 2,5-dibromobenzaldehyde, to obtain the 
central terphenylic rings, using a “Suzuki-type” Pd-catalyzed double cross-coupling 
reaction, with different boronic acids [44]. The final step is characterized by the formation 
of the oxazolone ring, adopting the “Erlenmeyer-Plöchl” condensation [45] (Scheme 5).   
 
 
 
Scheme 5: Synthesis of compound 13-20. 
 
To achieve the cross coupling, the catalyst Pd-Tetrakis-(triphenylphosphine)-palladium 
(Pd[P(Ph)3]4), is formed in situ, by a reaction of palladium acetate with an excess of 
triphenylphosphine, in an aqueous base and conventional heating at 100 °C overnight, 
reducing PdII to Pd0 (Scheme 6). This situation is preferred because of the high price of Pd 
(0)-complexes and due to its high instability.  The catalyst acts as a nucleophile by an 
oxidative addiction, to obtain the aryl-PdII-Br complex, which allow the subsequent 
transmetallation with the aryl-boronate. This step requires aqueous basic conditions, 
because the boronic acids are very stable compounds. The base makes the C-B bond, of the 
a: R = 4-F            e: R = 3-F   
b: R = 4-OCH3     f: R = 3-F, 4-OCH3 
c: R = 4-OCF3      g: R = 3,4-OCH2O- 
d: R = 4-CF3         h: R = 4-Cl  
                       
 
13: R = 4-F              17: R = 3-F 
14: R = 4-OCH3      18: R = 3-F, 4-OCH3 
15: R = 4-OCF3       19: R = 3,4-OCH2O- 
16: R = 4-CF3          20: R = 4-Cl                                
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boronic acid, more labile, and the boron atom negatively charged. The final step is the 
reductive elimination, where Pd0 is re-formed, and the product of the cross-coupling is 
obtained. In this situation we used double amount of the equivalents required for the aryl 
boronic acids, to have the double cross coupling reaction. 
 
 
Scheme 6: Catalysis cycle of the cross-coupling reaction. 
 
A second catalytic cycle is necessary to obtain the wanted terphenylic aldehyde, product of 
the double cross-coupling. We decided to use different boronic acids, to vary the 
substituents of the terphenylic system. The final step consists of the “Erlenmeyer-Plöchl” 
condensation: an initial acetylation of the N-acetyl-glycine, with Ac2O, then the enolate 
anion, formed in situ, attaches the carbonyl carbon of the terphenylic aldehyde. Finally, the 
addiction of the OH group over the carbonyl carbon (originated from the acetylated –COOH 
of N-Ac-glycine) leads to obtain the wanted oxazolone ring, with the elimination of AcOH. 
Chapter 3  MAGL inhibitors 
|56 
 
 
 
 
Scheme 7: Mechanism of the “Erlenmeyer-Plöchl” condensation. 
 
In order to enhance the yield of this second step, in the synthesis of compounds 13 and 14, 
we decided to double the amount of the equivalents required for AcONa and N-acetyl-
glycine. This change increased the yield, from 11% to 35%, for compound 13, but not for 
compound 14 (yields: approx. 20%). In all the successive attempt, using others boronic 
acids, I have always used this new procedure. In the case of compound 14, we have also 
tried another attempt, enhancing the time of the reaction (from 5h, to 48h), but the 
starting material aldehyde was still present, and other by-product were formed. 
 
Table 2: Optimization of “Erlenmeyer-Plöchl” condensation in compound 13 and 14. 
 
 EQUIVALENTS 
(REAGENTS) 
TIME 
(SYNTHESIS 
OF 13) 
YIELD 
(SYNTHESIS 
OF 13) 
TIME 
(SYNTHESIS 
OF 14) 
YIELD 
(SYNTHESIS 
OF 14) 
CLASSICAL 
PROCEDURE 
24a-b: 1eq. 
N-Ac-gly: 1eq 
AcONa: 1eq. 
5h 11% 5h 17% 
OPTIMIZED 
PROCEDURE 
24a-b: 1eq. 
N-Ac-gly: 2eq 
AcONa: 2eq. 
5h 35% 5h, 48h 19% 
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3.2.2  Synthetic attempts of compound 21-22 
  
During my thesis period I met some problems in the cases of two compounds, using the 
conditions described above (Scheme 5). We decided to adopt various modifications of the 
common procedure, especially in the cross-coupling step; but unfortunately the synthesis 
of compound 21-22 has not been possible.  
 
In the way to obtain compound 21, many procedures were tried (Scheme 8, 10, 11). The 
first attempt consists of an initial deprotection on the –OCH3 groups of compound 14, that 
was obtained by the classical synthetic procedure, using BBr3, in dry dichloromethane, to 
obtain the reached –OH group, but this reaction leads to the degradation of the oxazolone 
cycle, whereas the –OCH3 groups are maintained. Then we decided to reproduce the same 
deprotection, starting from the aldehyde 24b, followed by the “Erlenmeyer-Plöchl” 
reaction, to obtain the oxazolone. The –OH groups are obtained, but the absence of the 
aldehyde proton in 1H-NMR spectrum suggested that the high reactivity of the aldehydic 
group produces an unwanted compound. 
 
 
Scheme 8: First attempt to obtain compound 21.  
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The mechanism of the O-demethylation reaction is described below (Scheme 9) [46]. In this 
deprotection BBr3 is used, as a hard Lewis acid, in CH2Cl2, to obtain a complex, between the 
ethereal oxygen and the bore atom. Then the elimination of an alkyl bromide gives the 
formation of a dibromo-borane intermediate, which undergoes hydrolysis, forming the 
final –OH group. 
 
 
Scheme 9: Mechanism of the O-demethylation, using BBr3. 
 
The second attempt for compound 21 is characterized by an initial double cross-coupling, 
using 2,5-dibromobenzaldehyde, as staring material, and a (4-hydroxyphenyl) boronic acid, 
giving the terphenylic aldehyde 25, using classical Suzuki conditions. The next step is the 
condensation to form the oxazolone ring, using N-acetyl-glycine, Ac2O and AcONa, but in 
this case it was obtained the unwanted acetylated compound 26, instead of 21 (Scheme 
10). 
 
 
Scheme 10: Second attempt to obtain compound 21. 
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The third attempt we have tried, consists of a cross coupling reaction, using 2,5 
dibromobenzaldehyde, as staring material, and a (4-((tert-butyldimethylsilyl)oxy) phenyl) 
boronic acid, using classical Suzuki conditions, which did not lead to the wanted compound 
27. Then we decided to adopt a cross coupling reaction, in anhydrous conditions, followed 
by the “Erlenmeyer-Plöchl” condensation. The last expected step was the deprotection of 
the -OTBDMS groups, using tetra-n-butylammonium fluoride (TBAF), to obtain the reached 
–OH group (Scheme 11).  In the cross coupling we used K2CO3 as solid base, instead of an 
aqueous solution of Na2CO3. Moreover, we used only toluene as solvent, the boronic acid 
was increased from 3.2 to 4 equivalents, and the time of the reaction was reduced to 3h. 
Compound 27 was obtained with high yield in this way. Unfortunately, the following 
“Erlenmeyer-Plöchl” condensation led to the same situation of the second synthetic 
attempt, with the formation of acetylated compound 26, instead of compound 28.  
 
 
 
Scheme 11: Third attempt to obtain compound 21. 
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Table 3: Conditions used in the cross-coupling, with the 4-OTBDMS-phenyl boronic acid. 
 
Conditions 
of the 
reactions 
Catalyst Base Solvent Equivalent 
of boronic 
acid 
Time and 
temperature 
Yield 
Aqueous 
conditions 
Pd(OAc)2 
PPh3 
Na2CO3 
aq. 2M 
Toluene, 
EtOH 
3.2 24 h 
100 °C 
 
Anhydrous 
conditions 
Pd(OAc)2 
PPh3 
K2CO3 
dry 
Toluene 4 3 h 
100 °C 
94% 
 
With regard to compound 22, the synthesis starts with the double cross-coupling, under 
anhydrous conditions, using 2,5-dibromobenzaldehyde, as staring material, and (4-
cyanophenyl)boronic acid. The CN group is, in fact, subjected to an undesired hydrolysis 
under heating due to the presence of water in the reaction mixture. Therefore, this reaction 
did not lead to the terphenylic aldehyde 30, but it was obtained the mono-coupling product 
29. Then we tried a second cross-coupling, to attach the second phenyl ring, using 2 
equivalents of boronic acid, instead of 4, but neither in this case was compound 29 
obtained.  
 
 
Scheme 12: Attempt of synthesis of compound 22. 
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4.1. Inhibition assay 
The MAGL inhibitors, synthetized during my thesis work, were subjected to enzymatic 
inhibition assays on human MAGL, to achieve their IC50 values. The biological data of the 
terphenilic compounds, previously synthetized (from CG-946-B to CG-980-B), were 
included in Table 4 and used to compare the results.  
Table 4. Structures and IC50 of MAGL inhibitors. 
 
Structure 
 
 
Compound 
 
MW 
 
MAGL IC50 
 
 
CG-946-B 
 
339.39 
 
836.6 ± 
17.9 (nM) 
 
 
 
CG-964-B 
 
 
339.39 
 
 
545.9 ± 
20.3 (nM) 
 
 
 
CG-968-B 
 
 
339.39 
 
 
2.6 ± 0.2 
(µM) 
 
 
 
CG-974-B 
 
 
339.39 
 
 
456.6 ± 
10.2 (nM) 
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CG-980-B 
 
 
339.39 
 
 
319.9 ± 
10.2 (nM) 
 
 
 
 
13 
 
 
375.37 
 
 
683.2 ± 
49.7 (nM) 
 
 
 
14 
 
 
399.44 
 
 
347.9 ± 
37.6 (nM) 
 
 
 
15 
 
 
507.38 
 
 
4.2 ± 0.3 
(µM) 
 
 
 
16 
 
 
475.38 
 
 
6.7 ± 1.1 
(µM) 
 
 
 
17 
 
 
375.37 
 
 
627.8 ± 32.3 
(nM) 
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18 
 
 
 
 
435.42 
 
 
 
335.1 ± 1.6  
(nM) 
 
 
 
19 
 
 
427.41 
 
 
673.3 ± 23.0  
(nM) 
 
 
 
20 
 
 
408.28 
 
 
475.8 ± 38.5  
(nM) 
 
Among the several combinations of the terphenilic oxazolones, compound CG-980-B, 
characterized by the phenyl groups in position 2 and 5 of the central benzene, resulted to 
give the best IC50 value (319.9 ± 10.2 nM). On this base, we decided to introduce various 
substituent groups in different positions on the terphenilic structure, in order to analyse if 
the inhibition activity could be improved.  Between the new synthetized molecules, 
compound 18 showed the highest level of MAGL inhibition (IC50= 335.1 nM); moreover, 
compound 14 is to take into consideration (IC50= 347.9 ± 37.6 nM). These two molecules 
have in common the -OCH3 groups, in para positions of the peripheral phenilic rings, 
whereas compound 18 exhibited also the F atoms, in meta positions. However, compound 
17, exclusively characterized by m-F groups, showed a lower inhibition level (IC50= 627.8 
nM), suggesting that the –OCH3 groups are important to inhibit the enzyme. The negative 
effect of fluorine atoms was confirmed by the low activity of compound 13, showing an IC50 
value of 683.3 nM. The presence of a 1,3-benzodioxole group decreases the activity, as in 
compound 19 (IC50 = 673.3 nM). For what concern the para-dichloro substituted compound 
20, the inhibition level is quite satisfying (IC50= 475.8 nM). Differently, compounds 15 and 
16 (-OCF3 and –CF3 substituted, respectively) gave the worst results, with IC50 values in the 
micromolar range, confirming the detrimental effects of the presence of fluorine atoms for 
this class of compounds. In conclusion, the most interesting molecules are compound 18 
and 14, showing IC50 values comparable with the reference compound CG-980-B.
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Lysyl oxidase (LOX) and monoacylglycerol lipase (MAGL) are important pharmaceutical 
targets. The aim of this thesis work was the synthesis of their prospective inhibitors, to be 
tested as anticancer agents. As for LOX, the followed approach was the synthesis of 
hypoxia-activated prodrugs (HAP), because of the several side effects caused by a direct 
LOX inhibitor, such as β-aminoproprionitrile (BAPN). In details, we synthetized two 
prodrugs that are able to release β-aminoproprionitrile (Pro-BAPN) under hypoxic 
conditions. Considering that the nitro aromatic HAPs are efficient masking moieties, the 
design of the wanted compounds was based on previously synthetized nitroaryl Pro-BAPNs, 
characterized by different triggers. The peculiarity of my synthetic project was the 
introduction of 1-methyl-2-nitro-imidazole and 4-nitro-thiophene portions as triggers of 
the two Pro-BAPNs, and a methyl group as the linker with BAPN, to compare the effects 
given by the different aromatic heterocycles to the biological activities of these prodrugs. 
The generic synthetic pathway we used consists of a condensation step between the initial 
hetero-aromatic aldehyde and the amino-group of BAPN, followed by the reduction of the 
imine intermediate to an amine, which was finally converted into the corresponding 
hydrochloride salt. The obtained products are currently being evaluated for LOX inhibition 
and antiproliferative activity against cancer cells by Dr. Elisa Giovannetti, at the VU 
Amsterdam. The second part of my thesis project concerns a different molecular target: 
monoacylglycerol lipase (MAGL). Several compounds have already been reported in the 
literature to be good MAGL-inhibitors, by irreversibly binding the Ser122 residue of the 
enzyme catalytic site. However, these molecules cause desensitization and cross-tolerance 
to CB1 receptor agonists. For this reason we aimed at developing reversible MAGL 
inhibitors. One of the previously synthetized reversible inhibitors (compound CG-980-B) is 
characterized by a terphenilic structure. Notably, the central benzene ring bears two phenyl 
groups in position 2 and 5, and a 2-methyl-4-methylenoxazol-5(4H)-one scaffold in position 
1. Considering this fundamental structure, during my thesis work we introduced some 
different substituents in para and/or meta positions of the peripheral phenyl rings, in order 
to evaluate how these changes might influence the inhibitory activity. The synthetic 
pathway starts from 2,5-dibromobenzaldehyde, to obtain the substituted central 
terphenylic scaffold, using a “Suzuki-type” Pd-catalyzed double cross-coupling reaction 
with different boronic acids. The final step is characterized by the formation of the 
oxazolone ring by adopting the “Erlenmeyer-Plöchl” condensation. During this thesis work 
eight new compounds were obtained. In our department, Prof. Tiziano Tuccinardi analysed 
the final products, by means of enzymatic inhibition assays. Methoxy-substituted 
compounds 18 and 14 (Chapter 3, Scheme 5) proved to be the most potent inhibitors, with 
inhibitory potencies that are comparable with that of reference compound CG-980-B. In 
conclusion, the presence of at least one p-OCH3 group seems to be beneficial for the MAGL 
inhibitory activity of this class of compound.
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6.1. Material and methods 
Structure of synthesized compound was verified by 1H NMR and 13C NMR analysis. 
NMR spectra were obtained with a Bruker operating at 400MHz and relative to the solvent 
signal. 
Chemical shift (δ) are reported in parts per million (ppm), downfield from tetramethylsilane 
and referenced to the solvent residual peak. Coupling constants (J) are reported in Hz. 
The following abbreviations were used to explain the multiplicities: s = singlet, d = doublet, 
t = triplet, q = quartet, m = multiplet, dt = double triplet, ddd= double double doublet, dd = 
double doublet, bs = border signal, AA’XX’ = para-disubstituted system.  
Evaporation was performed under vacuum conditions in rotating evaporator. All reactions 
was monitored by thin-layer chromatography (TLC) using Merck aluminium silica gel (60 
F254) sheets that were visualized under a UV lamp (254 nm). Silica gel flash 
chromatography was performed using silica gel 60 (0.040-0.063 mm; Merck). Anhydrous 
sodium sulphate was always used as the drying agent. Commercially available reagents 
were purchased from Sigma Aldrich or Alfa Aesar, and used without purification.  Yields 
refer to isolated and purified products. 
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6.2. Lysyl oxidase inhibitors 
 
Compound 9 
 
 
Ethyl 2-amino-1-methyl-1H-imidazole-5-carboxylate 
 
Ethyl formate (45 mL) and the co-solvent dry THF (45 mL) were dropwise added, under 
argon atmosphere,  in a flame-dried two-necked round bottomed flask, containing the 
starting material sarcosine ethyl ester (6) (2.00 g, 13.0 mmol). The mixture was stirred to 
obtain a white suspension. Then a mineral oil dispersion of NaH 60% (5.20 g, 130 mmol) 
was added, at 0 °C, using an ice bath, and the stirring was maintained at room temperature 
for 3h. After this time a yellow suspension had formed, and the mixture was quenched with 
ice and distilled water, with formation of bubble and lather. The reaction mixture was 
initially extracted with AcOEt (X2). The aqueous phase was then treated with HCl 1N to give 
a second extraction with AcOEt (X2). The organic phase obtained from the acidified water 
was dried, filtered and concentrated in vacuum. The crude product 7 was a white solid (1.22 
g) that was used in the next step without further purification. Then compound 7 was 
dissolved in EtOH (40 mL), in a flame-dried two-necked round bottomed flask, then 
concentrated aqueous HCl was added (8 mL). The resulting yellow-brown solution was 
stirred, under reflux, at 105 °C, for 2h. After this time the mixture was left at room 
temperature; no precipitate had formed, reason why it was decided to proceed with the 
following reaction. The aqueous solution, containing intermediate 8, was diluted with EtOH 
(30 mL), and distilled water (30 mL). An aqueous 2M solution of NaOH (approx. 50 mL) was 
added to the mixture, to adjust the pH to 3. Finally it was added cyanamide (1.09 g, 26.0 
mmol), under argon atmosphere, and the orange solution obtained was heated under 
reflux for 1.5 h, at 120 °C. After this time the solution was cooled to ambient temperature, 
and concentrated under reduced pressure to approximately 1/8 of the original volume. The 
pH was then adjusted to 8-9 using solid K2CO3, again no precipitate had formed, so EtOH 
was completely removed under vacuum conditions. The organic phase was extracted with 
AcOEt (X2), dried, filtered and evaporated under reduced pressure. The crude product was 
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purified by column chromatography on silica gel, eluting with Dichloromethane/MeOH 
(95:5).  
Two fractions were obtained from this purification:  
- A, 820 mg (Compound 9 pure, as a yellow solid, 4.85 mmol);  
- B, 70.1 mg (Compound 9 with some impurities, as a yellow oil).  
 
The yield of this reaction, calculated over the three steps, was 37%. 
 
 
1H NMR (CDCl3) δ (ppm): 1.33 (t, 3H, J = 7.2 Hz); 3.67 (s, 3H); 4.26 (q, 2H, J = 7.2 Hz); 4.30-
4.38 (bs, 2H); 7.42 (s, 1H). 
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Compound 10 
 
 
Ethyl 1-methyl-2-nitro-1H-imidazole-5-carboxylate 
 
In a flame-dried two-necked round bottomed flask, containing an aqueous solution of 
NaNO2 (4.22 mL, 3.34 g, 48.3 mmol), pure compound 9 (817 mg, 4.83 mmol) in CH3COOH 
(8.46 mL) was added, in a drop wise manner, under argon atmosphere. The orange solution 
formed was stirred at room temperature for 4h. After this time the reaction mixture was 
extracted with CH2Cl2 (X2), washed with brine and with a saturated aqueous solution of 
Na2S2O3, then it was dried, filtered, and concentrated under reduce pressure. The crude 
product was purified by column chromatography on silica gel, eluting with n-Hexane/AcOEt 
(from 90% to 80% AcOEt). Compound 10 is obtained as a yellow solid (284 mg, 0.880 mmol).  
 
The yield of the reaction was 30%.  
 
 
1H NMR (CDCl3) δ (ppm): 1.40 (t, 3H, J = 7.0 Hz), 4.34 (s, 3H), 4.40 (q, 2H, J = 7.2 Hz), 7.74 (s, 
1H). 
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Optimization attempt of compound 10 
 
 
Ethyl 1-methyl-2-nitro-1H-imidazole-5-carboxylate 
With the aim of enhance the yield of this reaction, it was tried a little different procedure.  
In a flame-dried two-necked round bottomed flask, containing compound 9 (100 mg, 0.592 
mmol) in CH3COOH (1.04 mL), was added a solution of sodium nitrite (0.50 mL, 409 mg, 
5.92 mmol), previously prepared, in a drop wise manner, under argon atmosphere. The 
orange solution formed was stirred at room temperature for 4h. The successive treatment 
and purified were identical to those indicated above.  
The compound is obtained as a yellow solid (20.1 mg). 
 
1H NMR (CDCl3) δ (ppm): Spectrum difficult to interpret.  
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Synthetic attempt of compound 11 
 
 
 
2-amino-1-methyl-1H-imidazol-5-ol 
 
The fraction B of compound 9 (64.6 mg, 0.38 mmol) was dissolved in dry THF (2 mL), in a 
flame-dried two-necked round bottomed flask, under argon atmosphere. Dry MeOH (0.17 
mL) was added to solution, and then, using an ice bath at 0 °C, NaBH4 (43.1 mg, 1.14 mmol) 
was added, portion wise. The yellow reaction mixture was stirred at 0 °C for 45 min, and 
then at ambient temperature for 2h. After this time the reaction was quenched with ice 
and diluted with distilled water. The pH was adjust to 7-8, using solid NH4Cl. The organic 
phase was extracted with AcOEt (X2), dried, filtered and evaporated under reduced 
pressure. The crude product was purified by column chromatography on silica gel, eluting 
with Dichloromethane/MeOH (98:2). This purification lead to two fractions: 
- A, 4.1 mg (yellow oil); 
- B 6.4 mg (white solid). 
 
 
1H NMR (DMSO-d6) δ (ppm): In both cases spectra difficult to interpret were obtained, and 
no significant signals of the wanted compound were found.  
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Compound 12 
 
 
 
1-methyl-2-nitro-1H-imidazol-5-ol 
 
To a solution of compound 10 (278 mg, 1.40 mmol) in anhydrous THF (7.24 mL) and 
MeOH (0.60 mL), NaBH4 (159 mg, 4.20 mmol) was added, at 0 °C, portion wise and under 
argon atmosphere, in a flame-dried two-necked round bottomed flask. The yellow reaction 
mixture was stirred at 0 °C for 45 min, and then at ambient temperature for 1 h. After this 
time the mixture was quenched with ice and diluted with distilled water, then the pH was 
adjust to 7 using HCl 1M. The aqueous mixture was saturated with solid NaCl, then the 
organic phase was extracted with AcOEt (X3), dried, filtered, and concentrated under 
reduced pressure. The crude product was purified by column chromatography on silica gel, 
eluting with Dichloromethane/MeOH (98:2). Compound 12 was obtained as a yellow solid 
(116 mg, 0.739 mmol).  
 
The yield of the reaction was 53%. 
 
 
1H NMR (DMSO-d6) δ (ppm): 3.91 (s, 3H), 4.54 (d, 2H, J = 5.4 Hz), 5.48 (t, 1H, J = 5.4 Hz), 
7.11 (s, 1H). 
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Compound 3a 
 
 
 
1-methyl-2-nitro-1H-imidazole-5-carbaldehyde 
 
In a flame-dried two-necked round bottomed flask, containing a solution of compound 12 
(111 mg, 0.700 mmol) in acetone (0.66 mL), dry CH2Cl2 (5.94 mL), and dry MeOH (approx. 
2 mL), MnO2 (367 mg, 4.23 mmol) was added, under argon atmosphere. The dark 
suspension obtained was stirred at room temperature for 50h. After this time the mixture 
was treated using vacuum-filtration, through Celite®, and washed with CH2Cl2 (approx. 20 
mL). The filtrate was concentrated under reduced pressure, and the crude product was 
purified by column chromatography on silica gel, eluting with n-Hexane/AcOEt (7:3). 
Compound 3a was obtained as a white solid (77.5 mg, 0.500 mmol).  
 
The yield of reaction was 71%. 
 
 
1H NMR (CDCl3) δ (ppm): 4.35 (s, 3H), 7.81 (s, 1H), 9.93 (s, 1H). 
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Compound 5a 
 
 
 
3-(((1-methyl-2-nitro-1H-imidazol-5-yl) methyl)amino)propanenitrile 
 
In a flame-dried two-necked round bottomed flask, containing compound 3a (74.6 mg, 
0.480 mmol) dissolved in dry CH2Cl2 (3.3 mL), BAPN (β-aminopropanenitrile, 0.11 mL, 101 
mg, 1.44 mmol) was added via a syringe, under argon atmosphere. The yellow solution was 
stirred at room temperature overnight. The mixture was treated by evaporation in vacuum, 
and no purification or 1H-NMR was realized. Compound 4a was obtained as a yellow oil. 
The next step was conducted in a flame-dried two-necked round bottomed flask, 
containing compound 4a in dry MeOH (3.35 mL), NaBH4 (134 mg, 3.55 mmol) was added, 
portion wise, at -10 °C, using an ice bath with NaCl, under argon atmosphere. The yellow 
solution was stirred at room temperature for 1h. After this time the mixture was quenched 
with ice and diluted with distilled water. The organic mixture was extracted with CH2Cl2 
(X2), then it was washed with brine, dried, filtered and concentrated under reduced 
pressure. The crude product was purified by column chromatography on silica gel, eluting 
with n-Hexane/AcOEt (1:9). Compound 5a was obtained as a yellow-green oil (71.9 mg, 
0.340 mmol). 
 
 The yield of the reaction was 71%.  
 
 
1H NMR (CDCl3) δ (ppm): 1.57-1.72 (bs, 1H), 2.53 (t, 2H, J = 6.4 Hz), 2.96 (t, 2H, J = 6.4 Hz), 
3.90 (s, 2H), 4.08 (s, 3H), 7.06 (s, 1H).  
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Compound 1 
 
 
 
2-cyano-N-((1-methyl-2-nitro-1H-imidazol-5-yl) methyl)ethanaminium chloride 
 
In a round bottomed flask, containing compound 5a (68.7 mg, 0.330 mmol), dry MeOH 
(approx. 2 mL) was added to obtain a solution, under argon atmosphere. Then Et2O.HCl 
(approx. 4mL) was added until the precipitation of 1 was completed. The mixture was left 
to stand for some minutes, then it was filtered in vacuum, washing with Et2O. The 
precipitated was transferred in a vial, and concentrated in vacuum. The final compound 1 
was obtained as a white solid (49.3 mg, 0.200 mmol), sensible to the air.  
 
The yield of the reaction was 61%. 
 
 
1H NMR (D20) δ (ppm): 3.08 (t, 2H, J = 6.8 Hz), 3.59 (t, 2H, J = 6.8 Hz), 4.06 (s, 3H), 4.59 (s, 
2H), 7.44 (s, 1H). 
 
13C NMR (D20) δ (ppm): 14.82, 34.39, 40.08, 117.3, 128.3, 128.2, 129.8 (2C). 
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First synthetic attempt of compound 5b 
 
 
 
3-(((4-nitrothiophen-2-yl) methyl) amino) propanenitrile 
 
In a flame-dried two-necked round bottomed flask, containing compound 3b (250 mg, 1.59 
mmol) dissolved in dry CH2Cl2 (11 mL), BAPN (β-aminopropanenitrile, 0.35 mL, 334 mg, 4.77 
mmol) was added via a syringe, under argon atmosphere. The dark red solution obtained 
was stirred at room temperature overnight. The mixture was treated by evaporation in 
vacuum, and no purification or 1H-NMR were realized. The presumed compound 4b was 
obtained as a black solid. The following step was conducted in a flame-dried two-necked 
round bottomed flask, containing the black solid in dry MeOH (11 mL), NaBH4 (445 mg, 11.8 
mmol) was added, portion wise, at -10 °C, using an ice bath with NaCl, under argon 
atmosphere. A dark polymerized suspension was obtained, and it was stirred at room 
temperature for 1h. After this time the mixture was quenched with ice and diluted with 
distilled water, then the organic mixture was extracted with CH2Cl2 (X2). Then it was 
washed with brine, dried, filtered and concentrated under reduced pressure. The crude 
product was purified by column chromatography on silica gel, eluting with 
Dichloromethane/Methanol (98:2). The compound was obtained as a white solid (10.0 mg). 
 
 
1H NMR (CDCl3) δ (ppm): Spectrum difficult to interpret, and no characteristic signals of the 
wanted compound were found. 
 
 
 
 
 
 
 
 
Chapter 6  Experimental section 
  
|79 
 
Second synthetic attempt of compound 5b 
 
 
 
3-(((4-nitrothiophen-2-yl) methyl) amino) propanenitrile 
 
In a flame-dried two-necked round bottomed flask, containing compound 3b (250 mg, 1.59 
mmol) dissolved in dry MeOH (11 mL), BAPN (β-aminopropanenitrile, 0.35 mL, 334 mg, 4.77 
mmol) was added via a syringe, under argon atmosphere. The dark red solution obtained 
was stirred at room temperature overnight. The mixture wasn’t treated or purified, so it 
was decided to proceed with the following reaction in situ. In the two-necked round 
bottomed flask, containing the presumed, crude, compound 4b, NaBH4 (445 mg, 11.8 
mmol) was added, portion wise, at -10 °C, using an ice bath with NaCl, under argon 
atmosphere. A dark polymerized solution was obtained; it was stirred at room temperature 
for 1h. After this time the mixture was quenched with ice and diluted with distilled water, 
then the organic phase was extracted with CH2Cl2 (X2). Then it was washed with brine, 
dried, filtered and concentrated under reduced pressure. The high level of dark 
polymerization formed was a signal that the reaction was unsuccessful, so the crude 
product wasn’t purified and no 1H NMR was realized. 
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Compound 5b 
 
 
3-(((4-nitrothiophen-2-yl) methyl) amino) propanenitrile 
 
In a flame-dried two-necked round bottomed flask, containing compound 3b (250 mg, 1.59 
mmol) dissolved in dry MeOH (11 mL), BAPN (β-aminopropanenitrile, 0.35 mL, 334 mg, 4.77 
mmol) was added via a syringe, under argon atmosphere. The red solution obtained was 
stirred at room temperature for 2h. The mixture wasn’t treated or purified, so it was 
decided to proceed with the following reaction in situ.  In the flame-dried two-necked 
round bottomed flask, containing the crude compound 4b in dry MeOH (11 mL), NaBH4 
(445 mg, 11.8 mmol) was added, portion wise, at -10 °C, using an ice bath with NaCl, under 
argon atmosphere, and a dark solution, without polymerization signs, was obtained. This 
mixture was stirred at room temperature for 1h, and after this time it was quenched with 
ice and diluted with distilled water. The organic mixture was extracted with CH2Cl2 (X2), 
then it was washed with brine, dried, filtered and concentrated under reduced pressure. 
The crude product was purified by column chromatography on silica gel, eluting with n-
Hexane/ AcOEt (4:6). Compound 5b was obtained as a yellow solid (88.5 mg, 0.419 mmol).  
 
The yield of the reaction was of 26%. 
 
 
1H NMR (CDCl3) δ (ppm): 1.58-1.62 (bs, 1H), 2.54 (t, 2H, J = 6.5 Hz), 2.95 (t, 2H, J = 6.5 Hz), 
3.83 (d, 2H, J = 0.5 Hz), 7.43 (dt, 1H, J = 1.9, 0.9 Hz), 7.89 (d, 1H, J = 1.9 Hz). 
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Compound 2 
 
 
 
3-cyano-N-((4-nitrothiophen-2-yl) methyl) propan-1-aminium chloride 
 
In a round bottomed flask, containing compound 5b (84.8 mg, 0,400 mmol), dry MeOH 
(approx. 1 mL) was added to obtain a solution, under argon atmosphere. Then Et2O.HCl 
(approx. 0.1 mL) was added until the precipitation of 2 was completed. The mixture was 
left to stand for some minutes, then it was filtered in vacuum, washing with Et2O. The 
precipitated was transferred in a vial, and concentrated in vacuum. The final compound 2 
was obtained as a white-beige solid (56.7 mg, 0.702 mmol).  
 
The yield of the reaction was 57%. 
 
 
1H NMR (D20) δ (ppm): 3.04 (t, 2H, J = 6.8 Hz), 3.50 (t, 2H, J = 6.8 Hz), 4.37 (s, 1H), 8.01 (s, 
1H), 8.15 (s, 1H). 
 
13C NMR (D20) δ (ppm): 14.08, 42.30, 45.53, 117.39, 130.02, 130.39, 135.82 (2C). 
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6.3. Monoacylglycerol lipase inhibitors 
Compound 24a 
 
 
 
4,4''-difluoro-[1,1':4',1''-terphenyl]-2'-carbaldehyde 
 
In a sealed vial, Pd(OAc)2 (15.3 mg, 0.0630 mmol) and PPh3 (89.7 mg, 0.340 mmol) were 
dissolved in EtOH (2.6 mL) and toluene (2.6 mL). The solution formed was stirred, under 
argon atmosphere, for 10 minutes. Then, the 2,5-dibromobenzaldehyde starting material 
(300 mg, 1.14 mmol), Na2CO3 2M (2,6 mL) and (4-fluorophenyl)boronic acid (509 mg, 3.64 
mmol) were sequentially added to the vial. The obtained mixture was heated at 100 °C 
overnight. The vial was cooled to room temperature, then the mixture was diluted with 
distilled water and AcOEt. The organic mixture was extracted with AcOEt (X2), dried, 
filtered, and concentrated under reduced pressure. The crude product was purified by 
column chromatography on silica gel, eluting with n-Hexane/AcOEt (98:2). Compound 24a 
was obtained as a white crystalline solid (325 mg, 1.11 mmol).  
 
The yield of this reaction was 97%. 
 
 
1H NMR (CDCl3) δ (ppm): 7.15 (m, 4H), 7.39 (AA’XX’ 2H, JAX = 8.8 Hz, 4JHFm = 5.3 Hz,  JAA’/XX’ = 
2.5 Hz), 7.50 (d, 1H, J = 7.9 Hz), 7.63 (AA’XX’, 2H, JAX = 8.8 Hz, 4JHFm = 5.2 Hz, JAA’/XX’ = 2.6 Hz), 
7.83 (dd, 1H, J = 8.0, 2.1 Hz), 8.20 (d, 1H, J = 2.0 Hz), 10.24 (s, 1H). 
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Compound 13 
 
(Z)-4-((4,4''-difluoro-[1,1':4',1''-terphenyl]-2'-yl)methylene)-2-methyloxazol-5(4H)-one 
In a flame-dried two-necked round bottomed flask, containing compound 24a (312 mg, 
1.06 mmol), Ac2O (1.1 mL) was added, under argon atmosphere, giving a white suspension.  
Then N-acetyl-glycine (124 mg, 1.06 mmol) and AcONa (86.7 mg, 1.06 mmol) were added, 
and the mixture was stirred at 100 °C for 5h. After this time the obtained yellow solution 
was cooled to ambient temperature and diluted with distilled water and AcOEt.  The 
organic mixture was extracted with AcOEt (X2), washed with brine, dried, filtered, and 
evaporated under reduced pressure. The crude product was purified by column-
chromatography on silica gel, eluting with n-Hexane/AcOEt (98:2). This purification led to 
two fractions: 
- A, 98.9 mg (compound 24a) 
- B, 46.2 mg (compound 13, as a yellow solid, 0.123 mmol).  
The yield of this reaction was 11%. 
1H NMR (acetone-d6) δ (ppm): 2.42 (s, 3H), 7.06 (s, 1H), 7.28-7.33 (m, 4H), 7.48 (AA’XX’, 2H, 
JAX = 8.8 Hz, 4JHFm = 5.4 Hz, JAA’/XX’ = 2.2 Hz), 7.54 (d, 1H, J = 8.0 Hz), 7.79-7.84 (m, 3H), 9.04 
(d, 1H, J = 1.9 Hz). 
 
13C NMR (acetone-d6) δ (ppm): 15.71, 116.24 (d, 2C, J = 21.2 Hz), 116.68 (d, 2C, J = 21.1 Hz), 
128.23, 129.75 (d, 2C, J = 8.0 Hz), 129.81, 131.03, 131.86, 132.32, 132.74 (d, 2C, J = 8.0 Hz), 
134.75, 136.67 (d, J = 3.0 Hz), 137.26 (d, J = 3.0 Hz), 140.29, 143.29, 163.6 (d, J = 234.4 Hz), 
163.6 (d, J = 256.6 Hz), 168.07, 168.42. 
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 Optimized synthesis of compound 13  
 
 
(Z)-4-((4,4''-difluoro-[1,1':4',1''-terphenyl]-2'-yl)methylene)-2-methyloxazol-5(4H)-one 
In a sealed vial, containing compound 24a (96.3 mg, 0.330 mmol), Ac2O (0.34 mL) was 
added, under argon atmosphere, giving a white suspension.  Then N-acetyl-glycine (77.3 
mg, 0.660 mmol) and AcONa (54.1 mg, 0.660 mmol) were added, and the mixture was 
heated at 100 °C for 5h. After this time the obtained orange solution was cooled to ambient 
temperature and diluted with distilled water and AcOEt.  The organic mixture was extracted 
with AcOEt (X2), washed with brine, dried, filtered, and evaporated under reduced 
pressure. The crude product was purified by column-chromatography on silica gel, eluting 
with n-Hexane/AcOEt (98:2). Compound 13 was obtained as a yellow solid (46.5 mg, 0.124 
mmol).  
The yield of the reaction was 35%. 
 
1H NMR (CDCl3) δ (ppm): 2.43 (s, 3H), 7.14-7.21 (m, 5H), 7.32 (AA’XX’, 2H; JAX = 8.7 Hz, 4JHFm 
= 5.3 Hz, JAA’/XX’= 2.2 Hz), 7.44 (d, 1H, J = 8.1 Hz), 7.63-7.67 (m, 3H), 8.87 (d, 1H, J = 2.0 Hz). 
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Compound 24b 
 
 
4,4''-dimethoxy-[1,1':4',1''-terphenyl]-2'-carbaldehyde 
In a sealed vial, Pd(OAc)2 (15.3 mg, 0.0630 mmol) and PPh3 (89.7 mg, 0.340 mmol) were 
dissolved in EtOH (2.6 mL) and toluene (2.6 mL). The solution formed was stirred, under 
argon atmosphere, for 10 minutes. Then, the 2,5-dibromobenzaldehyde starting material 
(300 mg, 1.14 mmol), Na2CO3 2M (2,6 mL) and (4-methoxyphenyl)boronic acid (554 mg, 
3.64 mmol) were sequentially added to the vial. The obtained mixture was heated at 100 
°C overnight. The vial was cooled to room temperature, then the mixture was diluted with 
distilled water and AcOEt. The organic mixture was extracted with AcOEt (X3), dried, 
filtered, and concentrated under reduced pressure. The crude product was purified by 
column chromatography on silica gel, eluting with n-Hexane/AcOEt (98:2). Compound 24b 
was obtained as a white crystalline solid (363 mg, 1.14 mmol).  
 
The yield of this reaction was > 99%. 
 
 
1H NMR (CDCl3) δ (ppm): 3.87 (s, 3H), 3.88 (s, 3H), 7.00-7.03 (m, 4H), 7.34 (AA’XX’, 2H, JAX = 
8.8 Hz, JAA’/XX’ = 2.1 Hz), 7.49 (d, 1H, J = 8.0 Hz), 7.62 (AA’XX’, 2H, JAX = 8.9 Hz, JAA’/XX’ = 2.2 
Hz), 7.82 (dd, 1H, J = 8.0 2.1 Hz), 8.20 (d, 1H, J = 2.0 Hz), 10.05 (s, 1H). 
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Compound 14 
 
(Z)-4-((4,4''-dimethoxy-[1,1':4',1''-terphenyl]-2'-yl)methylene)-2-methyloxazol-5(4H)-one 
In a sealed vial, containing compound 24b (103 mg, 0.320 mmol),  Ac2O (0,32 mL) was 
added, under argon atmosphere, giving a white suspension.  Then N-acetyl-glycine (74.9 
mg, 0.640 mmol) and AcONa (52.5mg, 0.640 mmol) were added, and the mixture was 
heated at 100 °C for 5h. After this time the obtained orange solution was cooled to ambient 
temperature and diluted with distilled water and AcOEt.  The organic mixture was extracted 
with AcOEt (X2), washed with brine, dried, filtered, and evaporated under reduced 
pressure. The crude product was purified by column-chromatography on silica gel, eluting 
with n-Hexane/AcOEt (95:5).This purifications led to two fractions: 
- A, 42. 4 mg (compound 24b) 
- B, 23.8 mg (compound 14 as a yellow solid, 0.0596 mmol). 
 The yield of the reaction was 19%. 
1H NMR (CDCl3) δ (ppm): 2.42 (s, 3H); 3.86 (s, 3H), 3.87 (s, 3H), 6.98-7.04 (m, 5H), 7.27-7.29 
(m, 2H), 7.44 (d, 1H, J = 8.0 Hz), 7.63 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.6 Hz), 7.65-7.66 (m, 
1H), 8.85 (d, 1H, J = 2.0 Hz).  
 
1H NMR (acetone-d6) δ (ppm): 2.42 (s, 3H), 3.87 (s, 3H), 3.89 (s, 3H), 7.06-7.11 (m, 1H), 7.14 
(s, 1H), 7.35 (AA’XX’, 2H, J AX = 8.8 Hz, JAA’/XX’ = 2.6 Hz), 7.49 (d, 1H, J = 7.8 Hz), 7.70 (AA’XX’, 
2H, JAX = 8.9 Hz, JAA’/XX’ = 2.6 Hz), 7.77 (dd, 1H, J = 8.1, 2.1 Hz), 9.03 (d, 1H, J = 2.0 Hz). 
 
13C NMR (acetone-d6) δ (ppm): 15.71, 55.60, 55.65, 114.55 (2C), 114.76, 115.27 (2C), 
115.36, 128.67 (2C), 129.22, 129.46, 130.62, 131.70, 131.84 (2C), 131.99, 132.10, 139.79, 
140.48, 260.38, 166.44, 168.25 (2C). 
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Optimization attempt of compound 14 
 
(Z)-4-((4,4''-dimethoxy-[1,1':4',1''-terphenyl]-2'-yl)methylene)-2-methyloxazol-5(4H)-one 
In a sealed vial, containing compound 24b (37.4 mg, 0.12 mmol), Ac2O (0.12 mL) was added, 
under argon atmosphere, giving a white suspension.  Then N-acetyl-glycine (28.1 mg, 0.240 
mmol) and AcONa (19.7 mg, 0.240 mmol) were added, and the mixture was heated at 100 
°C for 48h. After this time it was obtained a brown suspension. The UV analysis, using TLC, 
has showed the presence in the mixture of the starting material aldehyde, and an 
intensification of other new spots, in addition to compound 14, consequently the 
purification was not performed. 
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Compound 24c 
 
 
 
4,4''-bis(trifluoromethoxy)-[1,1':4',1''-terphenyl]-2'-carbaldehyde 
In a sealed vial, Pd(OAc)2 (15.3 mg, 0.0630 mmol) and PPh3 (89.7 mg, 0.340 mmol) were 
dissolved in EtOH (2.6 mL) and toluene (2.6 mL). The solution formed was stirred, under 
argon atmosphere, for 10 minutes. Then, the 2,5-dibromobenzaldehyde starting material 
(300 mg, 1.14 mmol), Na2CO3 2M (2,6 mL) and (4-(trifluoromethoxy)phenyl)boronic acid 
(749 mg, 3.64 mmol) were sequentially added to the vial. The obtained mixture was heated 
at 100 °C overnight. The vial was cooled to room temperature, then the mixture was diluted 
with distilled water and AcOEt. The organic mixture was extracted with AcOEt (X2), dried, 
filtered, and concentrated under reduced pressure. The crude product was purified by 
column chromatography on silica gel, eluting with n-Hexane/AcOEt (99:1). Compound 24c 
was obtained as a white oil (432 mg, 1.01 mmol).  
 
The yield of this reaction was 89 %. 
 
 
1H NMR (CDCl3) δ (ppm): 7-33-7.37 (m 4H), 7.46 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.3 Hz), 
7.53 (d, 1H, J = 8.0 Hz), 7.69 (AA’XX’, 2H, JAX = 8.9 Hz, JAA’/XX’ = 2.3 Hz), 7.86 (dd, 1H, J = 8.0, 
2.2 Hz),  8.23 (d, 1H, J = 1.8 Hz), 10.0 (s, 1H). 
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Compound 15 
 
 
 
(Z)-4-((4,4''-bis(trifluoromethoxy)-[1,1':4',1''-terphenyl]-2'-yl)methylene)-2-methyloxazol-
5(4H)-one 
 
In a sealed vial, containing compound 24c (429 mg, 1.01 mmol), Ac2O (0.99 mL) was added, 
under argon atmosphere, giving a white suspension.  Then N-acetyl-glycine (236 mg, 2.02 
mmol) and AcONa (166 mg, 2.02 mmol) were added, and the mixture was heated at 100 °C 
for 5h. After this time the obtained brown solution was cooled to ambient temperature 
and diluted with distilled water and AcOEt. The organic mixture was extracted with AcOEt 
(X2), washed with brine, dried, filtered, and evaporated under reduced pressure. The crude 
product was purified by column-chromatography on silica gel, eluting with n-Hexane/AcOEt 
(98:2). Compound 15 was obtained as a yellow solid (161 mg, 0.317 mmol).  
 
The yield of the reaction was 32%. 
 
1H NMR (acetone-d6) δ (ppm): 2.43 (s, 3H), 7.06 (s, 1H), 7.50-7.52 (m, 4H), 7.56-7.61 (m, 
3H), 7.87-7.92 (m, 3H), 9.09 (d, 1H, J = 1.8 Hz) 
 
13C NMR (acetone-d6) δ (ppm): 15.74, 121.54 (q, 2C, J = 254.4 Hz), 121.6, 121.94, 122.51, 
127.87, 129.64 (2C), 129.97, 131.29, 131.99, 132.42, 132.64 (2C), 135.07, 139.52, 140.04, 
140.15, 141.5, 143.19, 149.83, 149.84, 168.00, 168.66. 
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Compound 24d 
 
 
 
4,4''-bis(trifluoromethyl)-[1,1':4',1''-terphenyl]-2'-carbaldehyde 
In a sealed vial, Pd(OAc)2 (15.3 mg, 0.0630 mmol) and PPh3 (89.7 mg, 0.340 mmol) were 
dissolved in EtOH (2.6 mL) and toluene (2.6 mL). The solution formed was stirred, under 
argon atmosphere, for 10 minutes. Then, the 2,5-dibromobenzaldehyde starting material 
(300 mg, 1.14 mmol), Na2CO3 2M (2,6 mL) and (4-(trifluoromethyl)phenyl)boronic acid (691 
mg, 3.64 mmol) were sequentially added to the vial. The obtained mixture was heated at 
100 °C overnight. The vial was cooled to room temperature, then the mixture was diluted 
with distilled water and AcOEt. The organic mixture was extracted with AcOEt (X2), dried, 
filtered, and concentrated under reduced pressure. The crude product was purified by 
column chromatography on silica gel, eluting with n-Hexane/AcOEt (99:1). Compound 24d 
was obtained as a white crystalline solid 425 mg, 1.11 mmol).  
 
The yield of this reaction was 95%. 
 
 
1H NMR (CDCl3) δ (ppm): 7.55-7.57 (m, 3H), 7.875-7.80 (m, 6H), 7.92 (dd, 1H, J = 8.0, 2.1 
Hz), 8.30 (d, 1H, J = 1.8 Hz), 10.03 (s, 1H). 
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Compound 16 
 
(Z)-4-((4,4''-bis(trifluoromethyl)-[1,1':4',1''-terphenyl]-2'-yl)methylene)-2-methyloxazol-
5(4H)-one 
In a sealed vial, containing compound 24d (421 mg, 1.10 mmol), Ac2O (1.1 mL) was added, 
under argon atmosphere, giving a white suspension.  Then N-acetyl-glycine (258 mg, 2.20 
mmol) and AcONa (180mg, 2.20 mmol) were added, and the mixture was heated at 100 °C 
for 5h. After this time the obtained brown solution was cooled to ambient temperature 
and diluted with distilled water and AcOEt. The organic mixture was extracted with AcOEt 
(X2), washed with brine, dried, filtered, and evaporated under reduced pressure. The crude 
product was purified by column-chromatography on silica gel, eluting with n-Hexane/AcOEt 
(98:2). Compound 16 was obtained as a yellow furry solid (260 mg, 0.547 mmol).  
 
The yield of the reaction was 54%. 
 
1H NMR (acetone-d6) δ (ppm): 2.44 (s, 3H), 7.06 (s, 1H), 7.04 (s, 1H), 7.65 (d, 1H, J = 8.0 
Hz), 7.70 (AA’XX’, 2H, JAX = 7.9 Hz), 7.90 (AA’XX’, 4H, JAX = 8.00 Hz), 7.96 (dd, 1H, J = 8.1, 2.0 
Hz), 8.02 (AA’XX’, 2H, JAX = 8.0 Hz), 9.16 (d, 1H, J = 2.0 Hz). 
 
13C NMR (acetone-d6) δ (ppm): 15.75, 125.36 (q, J = 271 Hz), 125,45 (q, J = 271 Hz), 
126.37 (q, 2C, J = 3.9 Hz), 126.91 (q, 2C, J = 3. 9 Hz), 127.46, 128.60, 130.14, 130.27 (q, J = 
36.0 Hz), 130.48 (q, J = 32.3 Hz), 131.57 (2C), 132.02, 132.51, 135.34, 140.33, 143.55, 
144.4 (q, 2C, J = 1.4 Hz), 144.7 (q, 2C, J = 1.4 Hz), 167.93, 168.87. 
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Compound 24e 
 
3,3''-difluoro-[1,1':4',1''-terphenyl]-2'-carbaldehyde 
In a sealed vial, Pd(OAc)2 (15.3 mg, 0.0630 mmol) and PPh3 (89.7 mg, 0.340 mmol) were 
dissolved in EtOH (2.6 mL) and toluene (2.6 mL). The solution formed was stirred, under 
argon atmosphere, for 10 minutes. Then, the 2,5-dibromobenzaldehyde starting material 
(300 mg, 1.14 mmol), Na2CO3 2M (2.6 mL) and (3-fluorophenyl)boronic acid (509 mg, 3.64 
mmol) were sequentially added to the vial. The obtained mixture was heated at 100 °C 
overnight. The vial was cooled to room temperature, then the mixture was diluted with 
distilled water and AcOEt. The organic mixture was extracted with AcOEt (X2), dried, 
filtered, and concentrated under reduced pressure. The crude product was purified by 
column chromatography on silica gel, eluting with n-Hexane/AcOEt (98:2). Compound 24e 
was obtained as a white oil (316 mg, 1.07 mmol).  
 
The yield of this reaction was 94%. 
 
 
1H NMR (CDCl3) δ (ppm): 7.08-7.14 (m, 1H), 7.15-7.20 (m, 3H), 7.36-7.39 (m, 1H), 7.44-7.49 
(m, 3H), 7.53 (d, 1H, J = 8.0 Hz), 7.87 (dd, 1H, J = 8.0, 2.1 Hz), 8.25 (d, 1H, J = 2.1 Hz), 10.04 
(s, 1H). 
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Compound 17 
 
(Z)-4-((3,3''-difluoro-[1,1':4',1''-terphenyl]-2'-yl)methylene)-2-methyloxazol-5(4H)-one 
In a sealed vial, containing compound 24e (156 mg, 0.530 mmol), Ac2O (0.52 mL) was 
added, giving a white suspension.  Then N-acetyl-glycine (124 mg, 1.06 mmol) and AcONa 
(86.9 mg, 1.06 mmol) were added, and the mixture was heated at 100 °C for 5h. After this 
time the obtained brown solution was cooled to ambient temperature and diluted with 
distilled water and AcOEt. The organic mixture was extracted with AcOEt (X2), washed with 
brine, dried, filtered, and evaporated under reduced pressure. The crude product was 
purified by column-chromatography on silica gel, eluting with n-Hexane/AcOEt (98:2). 
Compound 17 was obtained as a yellow solid (89.5 mg, 0.238 mmol).  
 
The yield of the reaction was 45%. 
 
1H NMR (acetone-d6) δ (ppm): 2.43 (s, 3H), 7.05 (s, 1H), 7.20-7.28 (m, 4H), 7.49-7.61 (m, 
5H), 7.87 (dd, 1H, J = 8.0, 2.0 Hz), 9.07 (d, 1H, J = 2.0 Hz). 
 
13C NMR (acetone-d6) δ (ppm): 15.75, 114.48 (d, J = 22.8 Hz), 115.44 (d, J = 21.3 Hz), 115.70 
(d, J = 21.3 Hz), 117.47 (d, J =22.0 Hz), 123.59 (d, J = 2.9 Hz), 126.95 (d, J = 2.9 Hz), 127.83, 
129.90, 132.22, 131.35 (d, J = 8.0 Hz) 131.88 (d, J = 10.0 Hz), 132.34, 135.02, 140.22, 142.69, 
143.29 (d, J = 7.3 Hz), 143.45, 143.47, 163.56 (d, J = 245.7 Hz), 164.25 (d, J = 244.3 Hz), 
168.02, 168.63.   
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Compound 24f 
 
 
3,3''-difluoro-4,4''-dimethoxy-[1,1':4',1''-terphenyl]-2'-carbaldehyde 
 
In a sealed vial, Pd(OAc)2 (15.3 mg, 0.0630 mmol) and PPh3 (89.7 mg, 0.340 mmol) were 
dissolved in EtOH (2.6 mL) and toluene (2.6 mL). The solution formed was stirred, under 
argon atmosphere, for 10 minutes. Then, the 2,5-dibromobenzaldehyde starting material 
(300 mg, 1.14 mmol), Na2CO3 2M (2.6 mL) and (3-fluoro-4-methoxyphenyl)boronic acid 
(619 mg, 3.64 mmol) were sequentially added to the vial. The obtained mixture was heated 
at 100 °C overnight. The vial was cooled to room temperature, then the mixture was diluted 
with distilled water and AcOEt. The organic mixture was extracted with AcOEt (X2), dried, 
filtered, and concentrated under reduced pressure. The crude product was purified by 
column chromatography on silica gel, eluting with n-Hexane/AcOEt (95:5). Compound 24f 
was obtained as a white crystalline solid (330 mg, 0.932 mmol).  
 
The yield of this reaction was 82%. 
 
 
1H NMR (CDCl3) δ (ppm): 3.96 (s, 3H), 3.97 (s, 3H), 7.05-7.12 (m, 3H), 7.19 (dd, 1H, J = 11.6, 
2.4 Hz), 7.39-7.43 (m, 2H), 7.48 (d, 1H, J = 8.1 Hz), 7.80 (dd, 1H, J = 8.0, 2.1 Hz), 8.18 (d, 1H, 
J = 2.0 Hz), 10.05 (s, 1H). 
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Compound 18 
 
(Z)-4-((3,3''-difluoro-4,4''-dimethoxy-[1,1':4',1''-terphenyl]-2'-yl)methylene)-2-
methyloxazol-5(4H)-one 
In a sealed vial, containing compound 24f (325 mg, 0.920 mmol),  Ac2O (0.90 mL) was 
added, under argon atmosphere, giving a white suspension.  Then N-acetyl-glycine (215 
mg, 1.84 mmol) and AcONa (151 mg, 1.84 mmol) were added, and the mixture was heated 
at 100 °C for 5h. After this time the obtained brown solution was cooled to ambient 
temperature and diluted with distilled water and AcOEt. The organic mixture was extracted 
with AcOEt (X2), washed with brine, dried, filtered, and evaporated under reduced 
pressure. The crude product was purified by column-chromatography on silica gel, eluting 
with n-Hexane/AcOEt (98:2).This purifications led to three fractions: 
- A, 79.2 mg (compound 24f) 
- B, 138 mg (compound 18 with a lot of impurities, as a yellow solid). 
- C, 49,2 mg (compound 18 pure, as a yellow solid, 0.113 mmol). 
 The yield of the reaction was 12%. 
1H NMR (acetone-d6) δ (ppm): 2.43 (s, 3H), 3.97 (s, 3H), 3.98 (s, 3H), 7.11 (s, 1H), 7.17 (ddd, 
1H, J = 8.4, 2.1, 1.1 Hz), 7.23 (dd, 1H, J = 12.1, 2.1 Hz), 7.26-7.32 (m, 2H) 7.51-7.57 (m, 3H), 
7.80 (dd, 1H, J = 8.1, 2.1 Hz), 9.01 (d, 1H, J = 2.0Hz).  
 
13C NMR (acetone-d6) δ (ppm): 15.75, 56.65, 56.69, 115.11 (d, J = 18.9 Hz), 115.09 (d, J = 
15.1 Hz), 118.2 (d, J = 18.4, 2C), 123.76 (d, J = 3.0 Hz). 127.18 (d, J = 3.4 Hz), 128.48. 129.47, 
130.71, 131.82, 132.26, 133.12 (d, J = 6.6 Hz), 133.83 (d, J = 6.3 Hz), 134.68, 139.71, 142.83, 
148.60 (d, J = 10.8 Hz), 148.63 (d, J = 10.3 Hz), 152.8 (d, J = 245.8 Hz), 153.48 (d, J = 244.7 
Hz), 168.15, 168.32. 
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Compound 24g 
 
2,5-bis(benzo[d][1,3]dioxol-5-yl)benzaldehyde 
In a sealed vial, Pd(OAc)2 (15.3 mg, 0.0630 mmol) and PPh3 (89.7 mg, 0.340 mmol) were 
dissolved in EtOH (2.6 mL) and toluene (2.6 mL). The solution formed was stirred, under 
argon atmosphere, for 10 minutes. Then, the 2,5-dibromobenzaldehyde starting material 
(300 mg, 1.14 mmol), Na2CO3 2M (2.6 mL) and benzo[d][1,3]dioxol-5-ylboronic acid (603 
mg, 3.64 mmol) were sequentially added to the vial. The obtained mixture was heated at 
100 °C overnight. The vial was cooled to room temperature, then the mixture was diluted 
with distilled water and AcOEt. The mixture was extracted with AcOEt (X2), dried, filtered, 
and concentrated under reduced pressure. The crude product was purified by column 
chromatography on silica gel, eluting with n-Hexane/AcOEt (9:1). Compound 24g was 
obtained as a white crystalline solid (296 mg, 0.855 mmol).  
 
The yield of this reaction was 75%. 
 
1H NMR (CDCl3) δ (ppm): 6.03 (s, 2H), 6.06 (s, 2H), 6.83 (dd, 1H, J = 7.8, 1.9 Hz), 6.90-6.93 
(m, 3H), 7.13-7.16 (m, 2H), 7,47 (d, 1H, J = 8.0 Hz), 7,77 (dd, 1H, J = 8.0, 2.1 Hz), 8.15 (d, 1H, 
J = 2.0 Hz), 10.05 (s, 1H). 
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Compound 19 
 
(Z)-4-(2,5-bis(benzo[d][1,3]dioxol-5-yl)benzylidene)-2-methyloxazol-5(4H)-one 
In a sealed vial, containing compound 24f (344 mg, .,99 mmol),  Ac2O (0.90 mL) was added, 
under argon atmosphere, giving a white suspension.  Then N-acetyl-glycine (232 mg, 1.98 
mmol) and AcONa (162 mg, 1.98 mmol) were added, and the mixture was heated at 100°C 
for 5h. After this time, the obtained brown solution was cooled to ambient temperature 
and diluted with distilled water and AcOEt. The organic phase was extracted with AcOEt 
(X2), washed with brine, dried, filtered, and evaporated under reduced pressure. The crude 
product was purified by column-chromatography on silica gel, eluting with n-Hexane/AcOEt 
(95:5). Compound 19 was obtained as a yellow solid (26.5 mg, 0.0620 mmol).  
The yield of this reaction was 13%. 
 
1H NMR (acetone-d6) δ (ppm): 2.42 (s, 3H), 6.09 (s, 2H), 6.11 (s, 2H), 6.86 (dd, 1H, J = 8.0, 
1.6 Hz), 6.92-7.00 (m, 3H), 7.13 (s, 1H), 7.23-7.26 (m, 2H), 7.48 (d, 1H, J = 8.0 Hz), 7.74 (dd, 
1H, J = 8.2, 2.2 Hz), 8.97 (d, 1H, J = 2.0 Hz). 
 
13C NMR (acetone-d6) δ (ppm):  15.73, 66.82, 66.93, 102.39, 102.49, 108.02, 109.04, 109.55, 
110.91, 121.47, 124.64, 128.92, 129.63, 130.82, 131.71, 132.22, 134.31, 135.23, 140.74, 
143.81, 148.61, 148.93, 149.48. 168.08, 168.22. 
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Compound 24h 
 
4,4''-dichloro-[1,1':4',1''-terphenyl]-2'-carbaldehyde 
In a sealed vial, Pd(OAc)2 (15.3 mg, 0.0630 mmol) and PPh3 (89.7 mg, 0.34 mmol) were 
diluted in EtOH (2.6 mL) and toluene (2.6 mL). The solution formed was stirred, under argon 
atmosphere, for 10 minutes. Then, the 2,5-dibromobenzaldehyde starting material (300 
mg, 1.14 mmol), Na2CO3 2M (2.6 mL) and (4-chlorophenyl)boronic acid (570 mg, 3.64 
mmol) were sequentially added to the vial. The obtained mixture was heated at 100 °C 
overnight. The vial was cooled to room temperature, then the mixture was diluted with 
distilled water and AcOEt. The mixture was extracted with AcOEt (X2), dried, filtered, and 
concentrated under reduced pressure. The crude product was purified by column 
chromatography on silica gel, eluting with n-Hexane/AcOEt (98:2). Compound 24h was 
obtained as a white crystalline solid (211 mg, 0.683 mmol).  
 
The yield of this reaction was 60%. 
 
 
1H NMR (CDCl3) δ (ppm): 7.36 (AA’XX’, 2H, JAX = 8.6 Hz, JAA’/XX’ = 2.3 Hz); 7.045-7.52 (m, 5H), 
7.61 (AA’XX’, 2H, JAX = 8.7 Hz, JAA’/XX’ = 2.3 Hz), 7.85 (dd, 1H, J = 8.0, 2.1 Hz), 8.22 (d, 1H, J = 
2.1 Hz), 10.03 (s, 1H). 
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Compound 20 
 
(Z)-4-((4,4''-dichloro-[1,1':4',1''-terphenyl]-2'-yl)methylene)-2-methyloxazol-5(4H)-one 
In a sealed vial, containing compound 24h (204 mg, 0.660 mmol), Ac2O (0.65 mL) was 
added, under argon atmosphere, giving a white suspension.  Then N-acetyl-glycine (155 
mg, 1.32 mmol) and AcONa (108 mg, 1.32 mmol) were added, and the mixture was heated 
at 100 °C for 5h. After this time the obtained brown solution was cooled to ambient 
temperature and diluted with distilled water and AcOEt. The organic phase was extracted 
with AcOEt (X2), washed with brine, dried, filtered, and evaporated under reduced 
pressure. The crude product was purified by column-chromatography on silica gel, eluting 
with n-Hexane/AcOEt (98:2). This purifications led to three fractions: 
- A, 74.6 mg (compound 24h) 
- B, 18.1 mg (compound 20 pure, as a yellow solid, 0.0443 mmol). 
- C, 8.50 mg (compound 20 with a lot of impurities, as a yellow crystalline solid). 
 
 The yield of the reaction was 7%. 
1H NMR (acetone-d6) δ (ppm): 2.43 (s, 3H), 7.05 (s, 1H), 7.46 (AA’XX’, 2H, JAX = 8.7 Hz, JAA’/XX’ 
= 2.3 Hz), 7.54-7.59 (m, 5H), 7.79 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.37 Hz), 7.85 (dd, 1H, J 
= 8.1, 2.0 Hz), 9.06 (d, 1H, J = 2.0 Hz). 
 
13C NMR (Acetone-d6) δ (ppm): 15.73, 127.95, 129.45 (2C), 129.54 (2C), 129.80, 130.03 
(2C), 131.10, 131.83, 132.34, 132.43 (2C), 134.42, 134.65, 134.95. 139.14. 139.61, 140.20, 
143.32, 168.01, 168.57. 
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First synthetic attempt of compound 21 
 
(Z)-4-((4,4''-dihydroxy-[1,1':4',1''-terphenyl]-2'-yl)methylene)-2-methyloxazol-5(4H)-one 
Compound 14 (37.6 mg, 0.0900 mmol) was dissolved in dry dichloromethane (1.1 mL), in a 
flame-dried two-necked round bottomed flask, then a solution of BBr3 1M in 
dichloromethane (0.60 mL) was added in a  drop wise manner, at -20 °C, using an ice bath 
with NaCl, under argon atmosphere. The mixture was stirred for 5 minutes, then it was 
maintained at 0 °C for 1 h. The orange solution obtained was then diluted with distilled 
water and the organic phase was extracted with AcOEt, washed with brine, dried, filtered, 
and evaporated in vacuum. The crude product wasn’t purified, and it was obtained as a 
yellow solid. 
 
1H NMR (acetone-d6) δ (ppm): Spectrum difficult to interpret, and no characteristic signals 
of the wanted compound were found.  
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Synthetic attempt of compound 25 
 
 
 
4,4''-dihydroxy-[1,1':4',1''-terphenyl]-2'-carbaldehyde 
 
Compound 23b (318.3 mg, 0.57 mmol) was dissolved in dry dichloromethane (6.6 mL), in a 
flame-dried two-necked round bottomed flask, then a solution of BBr3 1M in 
dichloromethane (3.60 mL) was added in a  drop wise manner, at -20 °C, using an ice bath 
with NaCl, under argon atmosphere. The mixture was stirred for 5 minutes, then was 
maintained at 0 °C for 1 h. The red solution obtained was then diluted with distilled water 
and the organic phase was extracted with AcOEt, washed with brine, dried, filtered, and 
evaporated under reduced pressure. The crude mixture was purified by column 
chromatography on silica gel, eluting with n-Hexane/AcOEt (7:3). The final product was 
obtained as a yellow solid (155 mg). 
 
1H NMR (acetone-d6) δ (ppm): Spectrum difficult to interpret. The signal of –OH groups 
were present, but no characteristic signal of the aldehyde was found.   
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Compound 25 
 
 
4,4''-dihydroxy-[1,1':4',1''-terphenyl]-2'-carbaldehyde 
In a sealed vial, Pd(OAc)2 (15.3 mg, 0.0630 mmol) and PPh3 (89.7 mg, 0.34 mmol) were 
dissolved in EtOH (2.6 mL) and toluene (2.6 mL). The solution formed was stirred, under 
argon atmosphere, for 10 minutes. Then, the 2,5-dibromobenzaldehyde starting material 
(300 mg, 1.14 mmol), Na2CO3 2M (2.6 mL) and (4-hydroxyphenyl)boronic acid (502 mg, 3.64 
mmol) were sequentially added to the vial. The obtained mixture was heated at 100 °C 
overnight. The vial was cooled to room temperature, then the mixture was acidified with 
HCl 1N. The organic mixture was extracted with AcOEt (X2), dried, filtered, and 
concentrated under reduced pressure. The crude product was purified by column 
chromatography on silica gel, eluting with n-Hexane/AcOEt (8:2). Compound 24 was 
obtained as a yellow solid (57.0 mg, 0.197 mmol).  
 
The yield of this reaction was 17%. 
 
1H NMR (acetone-d6) δ (ppm): 7.00 (AA’XX’, 4H, JAX = 8.9 Hz, JAA’XX’ = 2.5 Hz), 7.33 (AA’XX’, 
2H, JAX = 8.5 Hz, JAA’/XX’ = 2.37 Hz), 7.54 (d, 1H, J = 8.0 Hz), 7.62 (AA’XX’, 2H, JAX = 8.6 Hz, 
JAA’/XX’ = 2.46 Hz), 7.93 (dd, 1H, J = 8.0, 2.2 Hz), 8.11 (d, 1H, J = 1.8 Hz), 8.55 (s, 1H), 8.66 (s, 
1H), 10.03 (s, 1H). 
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Second synthetic attempt of compound 21 
 
(Z)-4-((4,4''-dihydroxy-[1,1':4',1''-terphenyl]-2'-yl)methylene)-2-methyloxazol-5(4H)-one 
In a sealed vial, containing compound 24 (53.9 mg, 0.186 mmol), Ac2O (0.19 mL) was added, 
under argon atmosphere, giving a white suspension.  Then N-acetyl-glycine (44.5 mg, 0.380 
mmol) and AcONa (31.2 mg, 0.38 mmol) were added, and the mixture was heated at 100 
°C for 5h. After this time the obtained solution was cooled to ambient temperature and 
acidified with HCl 1N. The organic mixture was extracted with AcOEt (X2), washed with 
brine, dried, filtered, and evaporated under reduced pressure. The crude product was 
purified by column-chromatography on silica gel, eluting with n-Hexane/AcOEt (8:2). This 
purification led to a white solid (16.3 mg). The obtained 1H NMR signals indicated the 
formation of compound 25, instead of 20.  
 
1H NMR (acetone-d6) δ (ppm): 2.30 (s, 3H), 2.32 (s, 3H), 7.30 (AA’XX’, 4H, JAX = 8.8 Hz, JAA’/XX’ 
= 2.5 Hz), 7.55 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.4 Hz), 7.65 (d, 1H, J = 8.0 Hz), 7.82 (AA’XX’, 
2H, JAX = 8.4 Hz, JAA’/XX’ = 2.4 Hz); 8.05 (dd, 1H, J = 8.2, 2.2 Hz), 8.21 (d, 1H, J = 2.1 Hz), 10.05 
(s, 1H). 
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Synthetic attempt of compound 27 
 
 
 
4,4''-bis((tert-butyldimethylsilyl)oxy)-[1,1':4',1''-terphenyl]-2'-carbaldehyde 
In a sealed vial, Pd(OAc)2 (4.49 mg, 0.0200 mmol) and PPh3 (89.7 mg, 0.34 mmol) were 
dissolved in EtOH (0.85 mL) and toluene (0.85 mL). The solution formed was stirred, under 
argon atmosphere, for 10 minutes. Then, the 2,5-dibromobenzaldehyde starting material 
(100 mg, 0.380 mmol), Na2CO3 2M (0.85 mL) and (4-((tert-
butyldimethylsilyl)oxy)phenyl)boronic acid (307 mg, 1.22 mmol) were sequentially added 
to the vial. The obtained mixture was heated at 100 °C overnight. The vial was cooled to 
room temperature, then the mixture was diluted with distilled water and AcOEt. The 
organic mixture was extracted with AcOEt (X2), dried, filtered, and concentrated under 
reduced pressure. The crude product was purified by column chromatography on silica gel, 
eluting with n-Hexane/AcOEt (8:2). This purifications led to two fractions: 
- A, 68.6 mg (as a white solid) 
- B, 52.2 mg (as a yellow solid). 
 
 
1H NMR (CDCl3) δ (ppm): In both cases spectra difficult to interpret were obtained, and no 
significant signals of the wanted compound were found.  
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Compound 27 
 
 
 
4,4''-bis((tert-butyldimethylsilyl)oxy)-[1,1':4',1''-terphenyl]-2'-carbaldehyde 
 
 
In a sealed vial, Pd(OAc)2 (6.56 mg, 0.0300  mmol) and PPh3 (38.6 mg, 0.147 mmol) were 
dissolved in toluene (4.76 mL). The solution formed was stirred, under argon atmosphere, 
for 10 minutes. Then, the 2,5-dibromobenzaldehyde starting material (128 mg, 0.490 
mmol), dry K2CO3 (203 mg, 1.47 mmol) and (4-((tert-butyldimethylsilyl)oxy)phenyl)boronic 
acid (475 mg, 1.96 mmol) were sequentially added to the vial. The obtained mixture was 
heated at 100 °C, for 3h. After this time vial was cooled to room temperature, then the 
mixture was diluted with distilled water and AcOEt. The organic mixture was extracted with 
AcOEt (X2), dried, filtered, and concentrated under reduced pressure. The crude product 
was purified by column chromatography on silica gel, eluting with n-Hexane/AcOEt (99:1). 
Compound 26 was obtained as a white oil (236 mg, 0.455 mmol).  
The yield of the reaction was 93%. 
 
1H NMR (CDCl3) δ (ppm): 0.24 (s, 6H), 0.26 (s, 6H), 1.01 (s, 9H), 1.02 (s, 9H), 6.94 (AA’XX’, 
4H, JAX = 8.5 Hz), 7.27-7.29 (m, 2H), 7.49 (d, 1H, J = 8.0 Hz), 7.55 (AA’XX’, 2H, JAX = 8.5 Hz), 
7.81 (dd, 1H, J = 8.1, 1.90Hz), 8.19 (d, 1H, J = 2.0 Hz), 10.04 (s, 1H). 
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Synthetic attempt of compound 28 
 
(Z)-4-((4,4''-bis((tert-butyldimethylsilyl)oxy)-[1,1':4',1''-terphenyl]-2'-yl)methylene)-2-
methyloxazol-5(4H)-one 
In a sealed vial, containing compound 26 (228 mg, 0.440 mmol), Ac2O (0.43 mL) was added, 
under argon atmosphere, giving a white suspension.  Then N-acetyl-glycine (103 mg, 0.880 
mmol) and AcONa (72.2 mg, 0.880 mmol) were added, and the mixture was heated at 100 
°C for 5h. After this time the obtained solution was cooled to ambient temperature and 
acidified with HCl 1N. The organic mixture was extracted with AcOEt (X2), washed with 
brine, dried, filtered, and evaporated under reduced pressure. The crude product was 
purified by column-chromatography on silica gel, eluting with n-Hexane/AcOEt (95:5). This 
purification led four fractions: 
- A, 30.6 mg (compound 26), 
- B, 45.8 mg (as a yellow solid), 
- C, 25.0 mg (as a yellow solid), 
- D, 33.7 mg (as a light yellow solid). 
In the case of B and C, spectra difficult to interpret were obtained, and no significant signals 
of the wanted compound were found. The 1H NMR signals of D, indicated the formation of 
compound 25, instead of 27.  
 
 
1H NMR (CDCl3) δ (ppm): 2.34 (s, 3H), 2. 35 (s, 3H), 7.21-7.25 (m, 4H), 7.43 (AA’XX’, 2H, JAX 
= 8.4 Hz, JAA’/XX’ = 2.4 Hz), 7.52 (d, 1H, J = 8.0 Hz), 7.68 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.4 
Hz), 7.85 (dd, 1H, J = 8.0 Hz, 2.0 Hz), 8.23 (d, 1H, J = 2.0 Hz), 10.06 (s, 1H). 
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First synthetic attempt of compound 30 
 
2'-formyl-[1,1':4',1''-terphenyl]-4,4''-dicarbonitrile 
In a sealed vial, Pd(OAc)2 (4.50 mg, 0.0200  mmol) and PPh3 (27.5 mg, 0.105 mmol) were 
dissolved in toluene (3.4 mL). The solution formed was stirred, under argon atmosphere, 
for 10 minutes. Then, the 2,5-dibromobenzaldehyde starting material (92.4 mg, 0.350 
mmol), dry K2CO3 (145 mg, 1.05 mmol) and (4-cyanophenyl)boronic acid (208 mg, 1.40 
mmol) were sequentially added to the vial. The obtained mixture was heated at 100 °C 
overnight. After this time vial was cooled to room temperature, then the mixture was 
diluted with distilled water and AcOEt. The organic mixture was extracted with AcOEt (X2), 
dried, filtered, and concentrated under reduced pressure. The crude product was purified 
by column chromatography on silica gel, eluting with n-Hexane/AcOEt (95:5. This 
purifications led to three fractions: 
- A, 49.4 mg (as a white crystalline solid), 
- B, 16.1 mg (as a white solid),  
- C, 50.0 mg (as a yellow solid) 
In the case of B and C, spectra difficult to interpret were obtained, and no significant signals 
of the wanted compound were found. The 1H NMR signals of A, indicated the formation of 
compound 29 (the mono-coupling product), instead of 30.  
 
 
1H NMR (CDCl3) δ (ppm) 7.30 (d, 1H, J = 8.4 Hz), 7.48 (AA’XX’, 2H, JAX = 8.4 Hz), 7.78-7.82 
(m, 3H), 8.17 ( d, 1H, J = 2.0 Hz), 9.87 (s, 1H).  
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Second synthetic attempt of compound 30 
 
 
2'-formyl-[1,1':4',1''-terphenyl]-4,4''-dicarbonitrile 
In a sealed vial, Pd(OAc)2 (1.12 mg, 5.10-03 mmol) and PPh3 (7.90 mg, 0.0300 mmol) were 
dissolved in toluene (1.7 mL) as solvents. The solution formed was stirred, under argon 
atmosphere, for 10 minutes. Then, the mono-coupling product of the previous reaction, 
compound 28, (46.0 mg, 0.170 mmol), dry K2CO3 (41.5 mg, 0.300 mmol) and (4-
cyanophenyl)boronic acid (51.4 mg, 0.350 mmol) were sequentially added to the vial. The 
obtained mixture was heated at 100 °C overnight. After this time vial was cooled to room 
temperature, then the UV analysis, using TLC, revealed the formation of the same 
compound C, obtained from the previous reaction. For this reason no treatment or 
purification were realized.
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